[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 700
6. Cheng CF, Huang WH, Tsai TP, Ko EW, Liao YF: Effects of cancer therapy on dental and maxillofacial development in children: report of case. ASDC J Dent Child; 2000 May-Jun;67(3):218-22, 161
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of cancer therapy on dental and maxillofacial development in children: report of case.
  • Malignant lymphoma is one of the most common hematological diseases of children.
  • The prognosis is fairly good with multimodal cancer therapy.
  • We reported a boy with Burkitt's lymphoma in the nasal cavity who received chemotherapy and irradiation of the head and neck area at four years of age.
  • During seven years of follow-up, we studied the developmental effects of cancer therapy, including general growth, maxillofacial bones, and dentition.
  • In the irradiated areas, the roots of teeth were short or poorly developed and the root apices showed premature closure.
  • After the patient was in remission from the tumor in his early childhood, the long-term effects of cancer therapy on dental and maxillofacial development are worth our further evaluation and follow-up.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Maxillofacial Development / drug effects. Nasal Cavity / drug effects. Nose Neoplasms / drug therapy
  • [MeSH-minor] Case-Control Studies. Child, Preschool. Follow-Up Studies. Growth / drug effects. Growth / radiation effects. Humans. Male. Mandible / drug effects. Mandible / radiation effects. Maxilla / drug effects. Maxilla / radiation effects. Radiotherapy, Adjuvant. Radiotherapy, High-Energy. Tooth / drug effects. Tooth / radiation effects. Tooth Apex / drug effects. Tooth Apex / radiation effects. Tooth Root / drug effects. Tooth Root / radiation effects

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10902084.001).
  • [ISSN] 1945-1954
  • [Journal-full-title] ASDC journal of dentistry for children
  • [ISO-abbreviation] ASDC J Dent Child
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


7. Aftandilian CC, Friedmann AM: Burkitt lymphoma with pancreatic involvement. J Pediatr Hematol Oncol; 2010 Nov;32(8):e338-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma with pancreatic involvement.
  • Intraoperative biopsies confirmed Burkitt lymphoma.
  • He was treated with multiagent chemotherapy.
  • He remains disease-free 6 years later.
  • Review of the literature demonstrates other cases of non-Hodgkin lymphoma with pancreatic involvement with good outcomes.
  • Pancreatic involvement is a relatively rare occurrence in childhood lymphoma.
  • [MeSH-major] Burkitt Lymphoma / pathology. Oropharyngeal Neoplasms / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930650.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Papatheodoridis GV, Hadziyannis SJ: Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther; 2004 Jan 1;19(1):25-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although, ideally, all patients with chronic hepatitis B should be treated, therapeutic intervention is currently recommended for cases with a relatively satisfactory likelihood of response and/or advanced disease.
  • A realistic therapeutic approach aims to sustain hepatitis B e antigen (HBeAg) loss and hepatitis B e antibody (anti-HBe) seroconversion in HBeAg-positive chronic hepatitis B and to sustain biochemical and virological remission in HBeAg-negative chronic hepatitis B.
  • Currently, three drugs are licensed for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil.
  • In patients with HBeAg-positive chronic hepatitis B, all of these drugs achieve HBeAg loss (24-33%) and anti-HBe seroconversion (12-30%) rates significantly superior to those observed in untreated placebo controls.
  • In patients with HBeAg-negative chronic hepatitis B, the sustained off-therapy response rate is 20-25% after a > or =12-month course of interferon-alpha and minimal (<10%), if any, after a 12-month course of lamivudine or adefovir.
  • Long-term adefovir achieves a response in approximately 70% of patients at 12 months, which is maintained at 24 months with rare (<2%) drug resistance.
  • Many other anti-viral agents, immunomodulatory approaches and combination therapies are currently being evaluated in chronic hepatitis B.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Drug Resistance, Viral. Forecasting. Humans. Retreatment. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14687164.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 106
  •  go-up   go-down


9. Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A, Rondelli R, De Rossi G, Lo Nigro L, Porta F, Santoro N, Indolfi P, Basso G, Conter V, Aricò M, Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP): Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica; 2001 May;86(5):478-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
  • The aim of this new study was to evaluate, for all risk groups: a) the efficacy of treatment intensification achieved by adding a fourth drug (daunomycin) in the induction phase and a 3-drug reinduction phase for all risk groups;.
  • DESIGN AND METHODS: From 1987 to 1991, a total of 632 eligible and evaluable children (age 1 to < or =16 years) with non-B-cell acute lymphoblastic leukemia (ALL), were enrolled and stratified as follows: standard risk (SR, 79 patients, 12.5%) had WBC <10,000/mm3, age > or = 3 and <7 years, and FAB L1 morphology.
  • The high risk (HR, 175 patients, 27.7%) group included patients with WBC > or =50,000/mm3 or FAB L3 morphology or T immunophenotype or acute undifferentiated leukemia (AUL) or leukemia-lymphoma syndrome.
  • All patients received a 4-drug induction therapy; intermediate-dose methotrexate was given to HR patients; cranial radiotherapy was given to IR and HR patients, while SR patients received extended intrathecal methotrexate; all patients received a 3-drug reinduction phase; high dose L-asparaginase (HD-L-ASP; E.Coli, Bayer) was given to HR patients; continuation therapy with 6-mercaptopurine, i.m. methotrexate, and monthly vincristine and prednisone pulses was given to all patients.
  • Treatment duration was 2 years.
  • The overall 10-year survival and event-free survival (EFS) rates (SE) are 74.7% (1.8) and 62.8% (2.0) respectively; EFS rates by risk group are 67.5% (5.5) in SR, 62.8% (2.6) in IR, and 61.9% (3.8) for HR.
  • INTERPRETATION AND CONCLUSIONS: When compared to the results of the AIEOP-ALL-82 study, treatment intensification in the ALL-87 study has improved long-term survival and EFS from 66.4% and 53.6% to 74.7% and 62.8%, respectively.
  • Failures were mostly due to marrow or extramedullary relapses suggesting that further treatment intensification, as being used in current therapeutic strategies, is appropriate, although patients relapsing after less intensive treatment may have better chances of rescue.
  • These results, although obtained in a relatively large proportion of patients, in which infants were not included, indicate that the addition of high-dose L-asparaginase to a relatively non-intensive treatment may be of major benefit for HR patients and that the addition of intrathecal methotrexate during CRT, may improve the central nervous system-disease control with a marked reduction of nervous system relapses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Child. Child, Preschool. Daunorubicin / administration & dosage. Female. Humans. Infant. Longitudinal Studies. Male. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Treatment Outcome. Vincristine / administration & dosage


10. Fredriksson A, Archer T: Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration. Behav Brain Res; 2003 Feb 17;139(1-2):31-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two experiments were performed to investigate the interactive effects of postnatal iron administration and adult MPTP treatment upon the function of C57 Bl/6 mice tested at adult age and to ascertain the possible ameliatory effects of a subthreshold dose of L-Dopa co-administered with different doses of the uncompetitive glutamate antagonist, MK-801.
  • Experiment II indicated that the deficits in motor activity parameters induced by postnatal iron at 7.5 mg/kg were alleviated in a dose-related manner by the co-administration of the uncompetitive glutamate antagonist, MK-801, with a subthreshold dose of L-Dopa.
  • The combination of MK-801 with L-Dopa increased locomotor (0.3 mg/kg), rearing (0.1 and 0.3 mg/kg) and total activity (0.3 mg/kg) of iron-treated mice during the initial, hypoactive 30-min period of testing.
  • The implications of iron overload in parkinsonism seem confirmed by the interactive effects of postnatal administration of the metal followed by adult MPTP treatment upon motor activity and the activity-enhancing effects of co-administration of L-Dopa with MK-801.
  • [MeSH-major] Behavior, Animal / drug effects. Dizocilpine Maleate / pharmacology. Iron / toxicity. Iron Overload / physiopathology. Levodopa / pharmacology. MPTP Poisoning / physiopathology
  • [MeSH-minor] Animals. Brain Chemistry / drug effects. Critical Period (Psychology). Dopamine Agents / pharmacology. Dose-Response Relationship, Drug. Drug Interactions. Drug Therapy, Combination. Habituation, Psychophysiologic / drug effects. Locomotion / drug effects. Male. Mice. Mice, Inbred C57BL. Motor Activity / drug effects. Neuroprotective Agents / pharmacology. Time

  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12642174.001).
  • [ISSN] 0166-4328
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dopamine Agents; 0 / Neuroprotective Agents; 46627O600J / Levodopa; 6LR8C1B66Q / Dizocilpine Maleate; E1UOL152H7 / Iron
  •  go-up   go-down


11. Kozlov IA, Poptsov VN: [Surfactant-BL and inhaled nitric oxide in acute respiratory distress syndrome in cardiac surgical patients]. Anesteziol Reanimatol; 2005 Nov-Dec;(6):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surfactant-BL and inhaled nitric oxide in acute respiratory distress syndrome in cardiac surgical patients].
  • The study was undertaken to evaluate lung function, central hemodynamics, and the oxygen transport system during combined therapy with surfactant-BL ("Biodurf", Saint Petersburg) and inhalational nitric oxide (iNO) for the acute respiratory distress syndrome (ARDS) after surgery using extracorporeal circulation (EC).
  • The diagnosis of ARDS was established in accordance with the criteria recommended by the USA-European Consensus Conference on ARDS.
  • Surfactant-BL was administered endobronchially.
  • Following 24 hours of the initiation of surfactant-BL therapy, there was a noticeable improvement of pulmonary oxygenizing function, a significant increase in P(a)O2 and SaO2 (p < 0.05), and a reduction in alveolar-arterial O2 differences and Qs/Qt.
  • The sensitivity of pulmonary oxygenizing function to iNO was enhanced by the administration of surfactant-BL.
  • On days 3-5 days after the detection of ARDS, there was, along with the improved gas-exchange function of the lung, a significant decrease in the severity of its damage according to the Murray scale.
  • It is concluded that the combined use of surfactant-BL and iNO ensures significantly improved pulmonary oxygenizing function, decreased thoracopulmonary compliance, and better O2 transport.
  • [MeSH-major] Extracorporeal Circulation / adverse effects. Nitric Oxide / therapeutic use. Postoperative Complications / drug therapy. Pulmonary Surfactants / therapeutic use. Respiratory Distress Syndrome, Adult / drug therapy
  • [MeSH-minor] Administration, Inhalation. Adult. Aged. Drug Therapy, Combination. Female. Heart Diseases / surgery. Hemodynamics. Humans. Lung / physiology. Lung / physiopathology. Male. Middle Aged. Pulmonary Gas Exchange. Pulmonary Ventilation. Respiratory Function Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499105.001).
  • [ISSN] 0201-7563
  • [Journal-full-title] Anesteziologiia i reanimatologiia
  • [ISO-abbreviation] Anesteziol Reanimatol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Pulmonary Surfactants; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


12. Papang R, John AS, Abraham S, Rao PS: A study of steroid-induced diabetes mellitus in leprosy. Indian J Lepr; 2009 Jul-Sep;81(3):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steroids, while still the most powerful drugs to manage leprosy reactions, predispose some patients to other morbidities such as diabetes, glaucoma, hypertension etc.
  • All leprosy patients with type 1 or type 2 reactions or neuritis admitted in 2006 to the Leprosy Mission Hospital in Kolkata, who had no past or current history and whose blood sugars on fasting were <126 mg/dl or postprandial <200 mg/dl were monitored fortnightly while on steroid therapy, estimating blood glucose by a glucometer using standard strips.
  • Compared to those who didn't, there were significantly more LL/BL patients with positive BI among SID whose cumulative prednisolone dosage was nearly 9000 mg as compared to half the amount among others.
  • Steroid induced diabetes is a serious complication among leprosy patients treated with prednisolone for reactions requiring careful monitoring for detection and appropriate clinical management.
  • [MeSH-major] Blood Glucose / analysis. Diabetes Mellitus / chemically induced. Glucocorticoids / adverse effects. Leprosy / drug therapy. Prednisolone / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. India / epidemiology. Male. Middle Aged. Prospective Studies. Young Adult


13. Magloire LK, Pettker CM, Buhimschi CS, Funai EF: Burkitt's lymphoma of the ovary in pregnancy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):743-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the ovary in pregnancy.
  • BACKGROUND: Burkitt's lymphoma is a rapidly growing and, if untreated, rapidly fatal tumor derived from B-lymphocytes.
  • The occurrence of Burkitt's lymphoma during pregnancy is rare.
  • CASE: A patient with Burkitt's lymphoma presented at 12 weeks of gestation with abdominal and tooth pain.
  • She underwent a left salpingo-oophorectomy with removal of the mass, as well as a tooth extraction.
  • The pathology examination confirmed lymphoma in the left ovary and in the tissue surrounding the extracted tooth.
  • After surgical resection, she was treated with multiagent chemotherapy beginning at 13 4/7 weeks of gestation.
  • CONCLUSION: The finding of an adnexal mass in conjunction with head and neck symptoms led to consideration of Burkitt's lymphoma.
  • Prompt treatment with multiagent chemotherapy should be considered for pregnant patients with Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tubes / surgery. Female. Gestational Age. Humans. Infant, Low Birth Weight. Infant, Newborn. Mouth Neoplasms / diagnosis. Mouth Neoplasms / drug therapy. Mouth Neoplasms / surgery. Ovariectomy. Pain. Pregnancy. Pregnancy Outcome. Tooth. Ultrasonography


1
Advertisement
4. Kabat-Koperska J, Kutrzeba J, Chosia M: [Acute kidney failure and ascites in Burkitt's lymphoma of the stomach]. Pol Arch Med Wewn; 2001 Jan;105(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute kidney failure and ascites in Burkitt's lymphoma of the stomach].
  • [Transliterated title] Ostra niewydolność nerek i wodobrzusze w przebiegu chłoniaka Burkitta zlokalizowanego w zoładku.
  • A case of 25 old man with acute renal failure as the result of uric acid nephropathy in Burkitt's lymphoma of the stomach and ascites, probably chylous, is presented.
  • After starting chemotherapy a regression of stomach tumor and the chylous effusion was observed.
  • Unfortunately, after a short period of remission the regression was observed with tumor lysis syndrome.
  • [MeSH-major] Acute Kidney Injury / complications. Ascites / complications. Burkitt Lymphoma / complications. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505701.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


15. Kamma JJ, Nakou M, Mitsis FJ: The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients. J Periodontol; 2000 Dec;71(12):1862-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients.
  • BACKGROUND: The purpose of this study was to evaluate the clinical and microbiological effects of systemic ornidazole (ORN) in sites with or without subgingival debridement in early-onset periodontitis (EOP) patients.
  • METHODS: Two pooled bacterial samples consisting of 4 sites each (scaled and non-scaled sites) were obtained from 30 individuals exhibiting EOP.
  • Bacterial samples were taken at baseline (BL) and 1 week and 2, 6, and 12 months after systemic ornidazole administration (500 mg/bid for 7 days).
  • After ORN administration, P. gingivalis, P. denticola, P. intermedia, B. forsythus, C. rectus, and S. sputigena were no longer detectable in either scaled or non-scaled sites.
  • A statistically significant long-term (2, 6, and 12 months) reduction of P. gingivalis, P. intermedia, P. loescheii, B. forsythus, and C. rectus and a pronounced increase of S. milleri, S. oralis, and S. sanguis counts in both scaled and non-scaled sites were detected in comparison to baseline.
  • A sustained reduction of bleeding tendency and of probing depth was also observed in both scaled and non-scaled sites.
  • CONCLUSIONS: ORN combined with SRP effects beneficial shifts in the bacterial population associated with substantial clinical improvement, thereby indicating that ORN is effective adjunct in the treatment of EOP deep periodontal pockets where anaerobic bacteria are predominant.
  • [MeSH-major] Aggressive Periodontitis / drug therapy. Anti-Bacterial Agents / therapeutic use. Ornidazole / therapeutic use. Subgingival Curettage
  • [MeSH-minor] Administration, Oral. Adult. Aggregatibacter actinomycetemcomitans / drug effects. Aggregatibacter actinomycetemcomitans / growth & development. Bacteroides / drug effects. Bacteroides / growth & development. Campylobacter / drug effects. Campylobacter / growth & development. Combined Modality Therapy. Dental Scaling. Female. Follow-Up Studies. Gingival Hemorrhage / drug therapy. Gingival Hemorrhage / therapy. Humans. Male. Oral Hygiene. Periodontal Pocket / drug therapy. Periodontal Pocket / therapy. Porphyromonas gingivalis / drug effects. Porphyromonas gingivalis / growth & development. Prevotella / drug effects. Prevotella / growth & development. Prevotella intermedia / drug effects. Prevotella intermedia / growth & development. Root Planing. Selenomonas / drug effects. Selenomonas / growth & development. Statistics, Nonparametric. Streptococcus / drug effects. Streptococcus / growth & development. Streptococcus oralis / drug effects. Streptococcus oralis / growth & development. Streptococcus sanguis / drug effects. Streptococcus sanguis / growth & development

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11156043.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 62XCK0G93T / Ornidazole
  •  go-up   go-down


16. Szczepanek J, Pogorzala M, Konatkowska B, Juraszewska E, Badowska W, Olejnik I, Kuzmicz M, Stanczak E, Malinowska I, Stefaniak J, Sobol G, Szczepanski T, Czyzewski K, Wysocki M, Styczynski J: Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res; 2010 Jun;30(6):2119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
  • The proteasome inhibitor, bortezomib, is known to be effective in the therapy of various neoplasms.
  • The objective of this study was the analysis of the ex vivo activity of bortezomib in paediatric acute lymphoblastic leukaemia (ALL), in comparison to paediatric acute myeloid leukaemia (AML).
  • A total of 159 patients entered the study, including 106 ALL (including 86 precursor-B-cell ALL, and 20 T-cell ALL) and 53 AML children.
  • The ex vivo sensitivity to bortezomib and 16 other drugs was studied by MTT assay.
  • Paediatric AML samples were more resistant than paediatric ALL samples to most of the tested drugs, except for cytarabine and thioguanine.
  • With respect to immunophenotype, ex vivo drug resistance in T-cell ALL (T-ALL) was higher for most of the drugs.
  • No differences in drug resistance between T-ALL and common/pre-B-cell-ALL were found for daunorubicin, mitoxantrone and 6-thioguanine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adolescent. Bortezomib. Child. Child, Preschool. Drug Resistance, Neoplasm. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651360.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


17. Chuah CT, Lim LC: Case report: acute tumour lysis syndrome. Ann Acad Med Singapore; 2001 Jan;30(1):55-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: acute tumour lysis syndrome.
  • INTRODUCTION: Acute tumour lysis syndrome (ATLS) is a potentially lethal but preventable complication of oncological treatment.
  • CLINICAL PICTURE: We report a case of a patient with Burkitt's leukaemia who developed ATLS after treatment with chemotherapy.
  • TREATMENT: Standard preventive measures using aggressive hydration, urine alkalinisation and uricosuric agents were instituted before chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Acute Disease. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Fatal Outcome. Humans. Male. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242627.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


18. Levy DS, Kahana JA, Kumar R: AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood; 2009 Feb 19;113(8):1723-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines.
  • We evaluated the effect of a novel, pan-AKT kinase inhibitor, GSK690693, on the proliferation of 112 cell lines representing different hematologic neoplasia.
  • Fifty-five percent of all cell lines tested were sensitive to AKT inhibitor (EC(50)<1 microM), with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and Burkitt lymphoma showing 89%, 73%, and 67% sensitivity to GSK690693, respectively.
  • The antiproliferative effect was selective for the malignant cells, as GSK690693 did not inhibit the proliferation of normal human CD4(+) peripheral T lymphocytes as well as mouse thymocytes.
  • Phosphorylation of downstream substrates of AKT was reduced in both sensitive and insensitive cell lines on treatment with GSK690693, suggesting that the cause of resistance was not related to the lack of AKT kinase inhibition.
  • Consistent with the role of AKT in cell survival, GSK690693 also induced apoptosis in sensitive ALL cell lines.
  • Overall, our data provide direct evidence for the role of AKT signaling in various hematologic malignancies, especially ALL and some lymphomas.
  • [MeSH-major] Apoptosis / drug effects. Oxadiazoles / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • [MeSH-minor] Animals. B-Lymphocytes / cytology. B-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / drug effects. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Drug Resistance, Neoplasm. Female. Humans. Leukemia, B-Cell / drug therapy. Leukemia, B-Cell / pathology. Lymphoma / drug therapy. Lymphoma / pathology. Mice. Mice, Inbred C57BL. Phosphorylation / drug effects. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064730.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GSK690693; 0 / Oxadiazoles; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


19. Lee WH, Deng ZD, Kim TS, Laine AF, Lisanby SH, Peterchev AV: Regional electric field induced by electroconvulsive therapy: a finite element simulation study. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:2045-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional electric field induced by electroconvulsive therapy: a finite element simulation study.
  • The goal of this study is to investigate the regional distribution of the electric field (E-field) strength induced by electroconvulsive therapy (ECT), and to contrast clinically relevant electrode configurations through finite element (FE) analysis.
  • An FE human head model incorporating tissue heterogeneity and white matter anisotropy was generated based on structural magnetic resonance imaging (MRI) and diffusion tensor MRI (DT-MRI) data.
  • We simulated the E-field spatial distributions of three standard ECT electrode placements [bilateral (BL), bifrontal (BF), and right unilateral (RUL)] and an investigational electrode configuration [focal electrically administered seizure therapy (FEAST)].
  • A quantitative comparison of the E-field strength was subsequently carried out in various brain regions of interests (ROIs) that have putative role in the therapeutic action and/or adverse side effects of ECT.
  • This study illustrates how the realistic FE head model provides quantitative insight in the biophysics of ECT, which may shed light on the differential clinical outcomes seen with various forms of ECT, and may guide the development of novel stimulation paradigms with improved risk/benefit ratio.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21096148.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH091083; United States / NCRR NIH HHS / RR / 5TL1RR024158-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Lacaud G, Gore L, Kennedy M, Kouskoff V, Kingsley P, Hogan C, Carlsson L, Speck N, Palis J, Keller G: Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. Blood; 2002 Jul 15;100(2):458-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report we demonstrate a role for Runx1 (AML1) at the hemangioblast stage of hematopoietic and endothelial development in embryonic stem (ES) cell-derived embryoid bodies (EBs).
  • Runx1 is expressed in EBs during the appearance of precursors with hemangioblast properties, the blast colony-forming cells (BL-CFCs).
  • Cell sorting studies revealed that all BL-CFCs within EBs express Runx1.
  • Runx1-deficient EBs consistently generate 10- to 20-fold fewer blast colonies than wild-type controls and display a complete block in definitive hematopoiesis.
  • These observations clearly demonstrate that Runx1 functions early in hematopoietic development, and they support the interpretation that the primitive erythroid lineage is established early by a subset of BL-CFCs that develop in a Runx1-independent fashion.
  • [MeSH-major] DNA-Binding Proteins / physiology. Embryo, Mammalian / cytology. Hematopoiesis / drug effects. Proto-Oncogene Proteins. Transcription Factors / physiology
  • [MeSH-minor] Animals. Cell Differentiation / genetics. Core Binding Factor Alpha 2 Subunit. Erythropoiesis / drug effects. Flow Cytometry. Gene Expression Profiling. Gene Expression Regulation, Developmental / physiology. Hematopoietic Stem Cells / metabolism. Mice. RNA, Messenger / analysis. Yolk Sac / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12091336.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL48834; United States / NHLBI NIH HHS / HL / R01 HL65169
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Runx1 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


26. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • The use of autologous stem cell transplantation appears to benefit patients who have had chemotherapy-sensitive relapses.
  • The role of allogeneic stem cell transplantation for this disease remains uncertain.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


27. Lin H, Sun XF, Zhen ZJ, Xia Y, Xiang XJ, Ling JY, Liu DG, Xia ZJ, Huang HQ, Luo WB, Zheng L, Lin TY, Guan ZZ: [Clinical analysis of 69 cases of Burkitt's lymphoma]. Ai Zheng; 2008 Apr;27(4):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 69 cases of Burkitt's lymphoma].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is a kind of highly aggressive B-cell lymphoma.
  • Its clinical characteristics are different between the endemic areas in Africa and the sporadic areas in America and Europe.
  • There is no large-scale report concerning Burkitt's lymphoma in China yet.
  • This study was to summarize the characteristics of Burkitt's lymphoma in China.
  • METHODS: Clinical data of 69 Burkitt's lymphoma patients, treated from May 1985 to May 2007 in Cancer Center of Sun Yat-sen University, were analyzed.
  • RESULTS: Of the 69 patients, 44 were men and 25 were women, with a median age of 7 (range, 2-72); 5 were at stage I, 9 at stage II, 21 at stage III, and 34 at stage IV, advanced stage (stages III and IV) accounted for 55 (79.7%) patients.
  • Abdomen (63.8%), cervical lymph nodes (68.1%) and faciomaxillary-oropharynx (34.8%) were the most common involved sites.
  • Short-term and high intensive chemotherapy with central nervous system prophylaxis could improve the prognosis.
  • CONCLUSION: The clinical characteristics of these 69 Burkitt's lymphoma patients are much similar to those from sporadic areas, but the median age is lower, and the most common involved sites are cervical lymph nodes, abdomen and faciomaxillary-oropharynx.
  • [MeSH-major] Burkitt Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423131.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


28. Moon Y, Kim M, Park G: Burkitt lymphoma with dual translocation of chromosome 14: a novel chromosomal abnormality of t(8;14),t(14;15). Ann Clin Lab Sci; 2008;38(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma with dual translocation of chromosome 14: a novel chromosomal abnormality of t(8;14),t(14;15).
  • Burkitt lymphomas (BLs) frequently show secondary chromosomal abnormalities.
  • Here, the authors describe a case of BL with an unusual dual translocation of chromosome 14, t(8;14) and t(14;15), and partial duplication of 1q.
  • Despite receiving CCG-106A chemotherapy, she was resistant to therapy and died on the 70th hospital day.
  • To our knowledge, this is the first documented case report of BL harboring dual translocation of chromosome 14 involving chromosomes 8 and 15, which may be a factor associated with unfavorable clinical course.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 8 / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316785.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Gal SZ, Wang J: [Clinical observation on drug-separated moxibustion at the navel for anti-aging]. Zhongguo Zhen Jiu; 2007 Jun;27(6):398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on drug-separated moxibustion at the navel for anti-aging].
  • OBJECTIVE; To observe clinical therapeutic effect and the mechanism of drug-separated moxibustion at the navel for delaying aging.
  • The group of drug-separated moxibustion at the navel (n=30) were treated with drug-separated moxibustion at the navel, twice each week; the acupuncture group (n=21) with acupuncture at Shenshu (BL 23) and Taixi (KI 3) as main points once each day; the western medicine group (n=20) with oral administration of vitamin E capsules, 0.
  • 1 g each time, twice daily.
  • Their clinical therapeutic effects, and changes of cumulative scores, serum SOD activities and MDA contents after treatment were compared among the 3 groups.
  • RESULTS: After treatment, clinical symptoms in the 3 groups very significantly improved (P < 0.01), with the group of drug-separated moxibustion at the navel more significantly improved (P < 0.01); in the 3 groups, SOD activities significantly increased (P < 0.01) and serum MDA contents significantly decreased (P < 0.01), and SOD activity and MDA content in the group of drug-separated moxibustion at the navel were not significantly different from those in the acupuncture group (P > 0.05), but significantly different from those in the western medicine group (P < 0.05).
  • CONCLUSION: The drug-separated moxibustion at the navel can significantly delay aging.
  • [MeSH-major] Acupuncture Therapy / methods. Aging. Moxibustion

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663099.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


30. Zhong XY, Su XX, Liu J, Zhu GQ: Clinical effects of acupuncture combined with nimodipine for treatment of vascular dementia in 30 cases. J Tradit Chin Med; 2009 Sep;29(3):174-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effects of acupuncture combined with nimodipine for treatment of vascular dementia in 30 cases.
  • OBJECTIVE: To study the therapeutic effects of acupuncture combined with nimodipine for vascular dementia.
  • METHODS: Acupuncture was applied at Baihui (GV 20), Shenshu (BL 23), Geshu (BL 17), and the points selected according to the midnight-noon, ebb-flow eight methods of the intelligent turtle, combined with the drug nimodipine.
  • The treatment was continued for 8 consecutive weeks.
  • RESULTS: Of the 30 cases treated, 6 cases were cured, 21 cases improved, and 3 cases failed, with a total effective rate of 90%.
  • CONCLUSION: Acupuncture at Baihui (GV 20), Shenshu (BL 23), Geshu (BL 17), and the points selected according to the midnight-noon, ebb-flow eight methods of the intelligent turtle combined with the drug nimodipine can yield definite therapeutic effects for vascular dementia.

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894378.001).
  • [ISSN] 0255-2922
  • [Journal-full-title] Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
  • [ISO-abbreviation] J Tradit Chin Med
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 57WA9QZ5WH / Nimodipine
  •  go-up   go-down


31. Guéniche A, Bastien P, Ovigne JM, Kermici M, Courchay G, Chevalier V, Breton L, Castiel-Higounenc I: Bifidobacterium longum lysate, a new ingredient for reactive skin. Exp Dermatol; 2010 Aug;19(8):e1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several recent human clinical trials clearly suggest that probiotic supplementation might be beneficial to the skin.
  • Using a probiotic lysate, Bifidobacterium longum sp. extract (BL), we demonstrated first in vitro, and then in a clinical trial, that this non-replicating bacteria form applied to the skin was able to improve sensitive skin.
  • The effect of BL were evaluated first on two different models.
  • Using ex vivo human skin explant model we found a statistically significant improvement versus placebo in various parameters associated with inflammation such as a decrease in vasodilation, oedema, mast cell degranulation and TNF-alpha release.
  • Moreover, using nerve cell cultures in vitro, we showed that after 6 h of incubation in culture medium (0.3-1%), the probiotic lysate significantly inhibited capsaicin-induced CGRP release by neurones.
  • The results demonstrated that the volunteers who applied the cream with bacterial extract had a significant decrease in skin sensitivity at the end of the treatment.
  • Moreover, the treatment led to increase skin resistance against physical and chemical aggression compared to the group of volunteers who applied the control cream.
  • Clinical and self-assessment scores revealed a significant decrease in skin dryness after 29 days for volunteers treated with the cream containing the 10% bacterial extract.
  • These findings suggest that new approaches, based on a bacteria lysate, could be developed for the treatment and/or prevention of symptoms related to reactive skin.
  • [MeSH-major] Bifidobacterium. Emollients / therapeutic use. Probiotics / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Biopsy. Calcitonin Gene-Related Peptide / metabolism. Capsaicin / pharmacology. Cells, Cultured. Dermatitis / drug therapy. Dermatitis / pathology. Double-Blind Method. Female. Humans. Middle Aged. Pilot Projects. Sensory Receptor Cells / drug effects. Sensory Receptor Cells / metabolism. Sensory System Agents / pharmacology. Skin / drug effects. Skin / metabolism. Skin / pathology. Substance P / adverse effects. Treatment Outcome. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. CAPSAICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624730.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Emollients; 0 / Sensory System Agents; 0 / Tumor Necrosis Factor-alpha; 33507-63-0 / Substance P; 83652-28-2 / Calcitonin Gene-Related Peptide; S07O44R1ZM / Capsaicin
  •  go-up   go-down


32. Schmitz N, Buske C, Gisselbrecht C: Autologous stem cell transplantation in lymphoma. Semin Hematol; 2007 Oct;44(4):234-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in lymphoma.
  • High-dose therapy (HDT) followed by autologous transplantation of hematopoietic stem cells (ASCT) is frequently performed in patients with lymphoma.
  • In Hodgkin's disease (HD), HDT/ASCT is a standard indication for patients with chemosensitive first relapse.
  • Patients with indolent or aggressive B-cell lymphoma may benefit from HDT/ASCT if considered as part of first-line therapy or at the time of relapse.
  • However, new randomized studies comparing HDT/ASCT with optimal chemoimmunotherapy are necessary because the introduction of monoclonal antibodies (rituximab) significantly improved the results of conventional chemotherapy.
  • Because data on patients with less frequent entities like mantle cell lymphoma, T-cell lymphoma, Burkitt's lymphoma, or lymphoblastic lymphoma are insufficient, the role of HDT/ASCT needs further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / drug therapy. Lymphoma / surgery. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Burkitt Lymphoma / mortality. Burkitt Lymphoma / therapy. Combined Modality Therapy. Disease-Free Survival. Evidence-Based Medicine. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Humans. Lymphoma, Follicular / mortality. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / mortality. Lymphoma, Mantle-Cell / therapy. Middle Aged. Transplantation, Autologous / utilization. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961722.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 53
  •  go-up   go-down


33. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V, Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr; 2007 Feb 1;44(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
  • OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).
  • METHODS: We analyzed the Grupo de Estudio del SIDA register of systemic ARL, which started in Jan 1994, to collect cases diagnosed at 15 institutions prospectively and with active follow-up every 6 months.
  • RESULTS: During the study period, 210 consecutive patients were diagnosed with ARL, with a median age 39 of years, 75.7% of whom were male, and with a median baseline CD4 count of 160 cells/microL.
  • Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).
  • Chemotherapy with or without other modalities was administered to 186 (88.6%) patients.
  • In an intent-to-treat analysis of 184 patients who received at least 1 chemotherapy course with adequate follow-up to assess their response, 119 (64.7%) achieved CR, and the median length of survival (Kaplan-Meier analysis) was 52 months (95% confidence interval [CI]: 23 to 82 months).
  • The single factor independently associated with disease-free survival was Ann Arbor stage.
  • CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.
  • The CR rate was poorer in patients with BL and TC subtypes and was inversely correlated with IPI score.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117144.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


34. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet; 2004 May;36(5):453-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
  • The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-positive (Ph(+)) chronic myeloid leukemia (CML) in chronic phase but is much less effective in CML blast crisis or Ph(+) B-cell acute lymphoblastic leukemia (B-ALL).
  • Here, we show that Bcr-Abl activated the Src kinases Lyn, Hck and Fgr in B-lymphoid cells.
  • The kinase inhibitor CGP76030 impaired the proliferation of B-lymphoid cells expressing Bcr-Abl in vitro and prolonged survival of mice with B-ALL but not CML.
  • The biochemical target of CGP76030 in leukemia cells was Src kinases, not Bcr-Abl.
  • These results implicate Src family kinases as therapeutic targets in Ph(+) B-ALL and suggest that simultaneous inhibition of Src and Bcr-Abl kinases may benefit individuals with Ph(+) acute leukemia.
  • [MeSH-major] Burkitt Lymphoma / enzymology. Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. src-Family Kinases / physiology
  • [MeSH-minor] Animals. Benzamides. Cell Division / drug effects. Drug Therapy, Combination. Enzyme Activation. Enzyme Inhibitors / pharmacology. Humans. Imatinib Mesylate. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Knockout. Piperazines / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / physiology. Proto-Oncogene Proteins / antagonists & inhibitors. Proto-Oncogene Proteins / physiology. Proto-Oncogene Proteins c-hck. Pyrimidines / pharmacology. Pyrroles / pharmacology


35. Cheung TW: AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma. Cancer Invest; 2004;22(5):787-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma.
  • The impact of highly active antiretroviral therapy (HAART) on the incidence of non-Hodgkin's lymphoma was less obvious initially, although primary central nervous system lymphoma (PCNSL) has dropped precipitously since the introduction of HAART.
  • The pathogenesis of acquired immunodeficiency syndrome-related lymphoma is multifactorial.
  • Epstein-Barr virus plays a significant role in these diseases, especially Burkitt lymphoma and PCNSL.
  • Data regarding the effect of HAART on the natural history and treatment outcomes of these malignancies are emerging.
  • The possibility of direct and indirect roles of human immunodeficiency virus in the carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment for these malignancies.
  • The simultaneous administration of HAART and chemotherapy does not appear to significantly alter the toxicity profile, although the information with respect to the interaction of HAART and chemotherapy is limited.
  • The use of biological agents, for example, monoclonal antibody against CD-20, is being explored to improve the clinical outcome of this disease.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma / immunology. Lymphoma / virology. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology


36. Fujishima N, Fujishima M, Inomata M, Yamanaka Y, Saitoh K, Kameoka Y, Yoshioka T, Saitoh H, Takahashi N, Hirokawa M, Sawada K: [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy]. Rinsho Ketsueki; 2007 Apr;48(4):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
  • A 43-year-old female was admitted with therapy-resistant pancreatitis and an abdominal tumor around the pancreatic head.
  • Laboratory data revealed leukocytosis with a white blood cell count of 18200/microl, 25% atypical cells and an LDH of 13410 IU/l.
  • The bone marrow was comprised of 78.4 percent lymphoblastoid cells which were positive for CD10, CD19 and CD20, and the cytogenetic study of which demonstrated the presence of t(8;14) (q24;q32) and t(14;18) (q32;q21) in the same clone.
  • The patient was diagnosed as having Burkitt's lymphoma (BL) with t(8;14) and t(14;18).
  • Although CODOX-M and IVAC therapy combined with rituximab achieved complete remission, she died of rapid progressive disease during whole brain irradiation before autologous peripheral blood stem cell transplantation.
  • Even if the intensive chemotherapy with rituximab is given adequately, durable remission may not be achieved in BL with translocation of t(8;14) and t(14;18).
  • A more effective therapy remains to be established for the treatment of this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Methotrexate / administration & dosage. Recurrence. Remission Induction. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515125.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


37. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB: Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal; 2008 Jun;20(6):1198-208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
  • Vascular endothelial growth factor (VEGF) is a survival and angiogenesis factor that is a target for therapy in a variety of cancers.
  • In many hematological malignancies, VEGF production is increased leading to cell survival responses.
  • Herein, we demonstrate that lysophosphatidic acid (LPA) induces mRNA expression of VEGF in the multiple myeloma cell line, U266, the Burkitt's lymphoma cell line, BJAB, and the chronic lymphocytic leukemia (CLL)-like cell line, I-83.
  • Secretion of VEGF was also increased in these cells following LPA treatment.
  • LPA treatment also caused the activation of both VEGFR1 and VEGFR2.
  • The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression.
  • Taken together, this indicates that LPA contributes to VEGF production in B cell malignancies leading to cell survival.
  • [MeSH-minor] Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Cell Line, Tumor. Gene Expression / drug effects. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Multiple Myeloma / genetics. Multiple Myeloma / metabolism. Mutagens / toxicity. NF-kappa B / metabolism. RNA, Messenger / metabolism. Vidarabine / analogs & derivatives. Vidarabine / toxicity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396013.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lysophospholipids; 0 / Mutagens; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 22002-87-5 / lysophosphatidic acid; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


38. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood; 2009 Oct 22;114(17):3533-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
  • Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC oncogene rearrangement (MYC+).
  • The prognostic significance of MYC+ DLBCL was determined in an unselected population of patients with newly diagnosed DLBCL treated with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP).
  • The diagnosis of MYC+ DLBCL is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in all patients with DLBCL.
  • In the R-CHOP treatment era, MYC+ DLBCLs have an inferior prognosis.
  • Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Rearrangement. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult


39. Sigusch B, Beier M, Klinger G, Pfister W, Glockmann E: A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis. J Periodontol; 2001 Mar;72(3):275-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis.
  • BACKGROUND: In the last few years knowledge about periodontal infections has increased enormously, nevertheless practitioners are still seeking guidelines for suitable treatment concepts.
  • METHODS: The aim of this study was to examine the effect of doxycycline, metronidazole, and clindamycin used adjunctively in a 2-step nonsurgical procedure in patients with rapidly progressive periodontitis (RPP).
  • The second step included full-mouth enhanced root planing (RP) and wound dressing in 1 or 2 visits after SRP and the beginning of antibiotic therapy.
  • Forty-eight patients (mean age 32.4 years) with generalized RPP, with an average of 16 sites with probing depths (PD) deeper than 8 mm, and high counts of Porphyromonas gingivalis were randomly assigned to 4 different groups: group 1 (doxycycline) n = 12, group 2 (metronidazole) n = 15, group 3 (clindamycin) n = 11, and group 4 (control group; no antibiotic treatment) n = 10.
  • Clinical evaluations, including plaque index (PI), sulcus bleeding index (SBI), probing depth (PD), clinical attachment level (CAL), and bacteriological and crevicular cell sampling, were done at baseline (BL), 3 weeks after SRP, and 6 and 24 months after RP.
  • After 24 months, the attachment level gain in group 1 and group 4 was less than 1.5 mm, and less than 1.0 mm in PD site categories 6 to 9 mm and >9 mm.
  • CONCLUSIONS: The present results show that metronidazole and clindamycin are effective antibiotics when used adjunctively in a 2-step nonsurgical procedure of scaling and root planing in RPP patients.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Periodontitis / drug therapy
  • [MeSH-minor] Adult. Aggregatibacter actinomycetemcomitans / drug effects. Aggregatibacter actinomycetemcomitans / growth & development. Clindamycin / therapeutic use. Clinical Protocols. Dental Plaque Index. Dental Prophylaxis. Dental Scaling. Doxycycline / therapeutic use. Female. Follow-Up Studies. Gingival Hemorrhage / drug therapy. Gingival Hemorrhage / therapy. Humans. Male. Metronidazole / therapeutic use. Neutrophils / drug effects. Neutrophils / physiology. Periodontal Attachment Loss / drug therapy. Periodontal Attachment Loss / therapy. Periodontal Index. Periodontal Pocket / drug therapy. Periodontal Pocket / therapy. Phagocytosis / drug effects. Porphyromonas gingivalis / drug effects. Porphyromonas gingivalis / growth & development. Root Planing. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. CLINDAMYCIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11327054.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 140QMO216E / Metronidazole; 3U02EL437C / Clindamycin; N12000U13O / Doxycycline
  •  go-up   go-down


40. Burke MJ, Dayton V: Treatment of a CNS relapse while on therapy for Burkitt lymphoma. Pediatr Blood Cancer; 2009 Feb;52(2):290-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of a CNS relapse while on therapy for Burkitt lymphoma.
  • The treatment of Burkitt lymphoma (BL) has come a long way in regards to survival, with the majority of even the advanced stage patients being cured.
  • The prognosis for relapsed BL remains dismal, despite attempts to further intensify therapy.
  • We report on a patient with advanced stage BL who relapsed in the CNS while on therapy.
  • The patient was successfully treated with an intensified regimen based on a concentration times time (C x T) CNS-directed model.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Child. Dose-Response Relationship, Drug. Humans. Male. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937319.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Van Gool SW, Van Kerschaver E, Brock P, Pottel H, Hulstaert F, Vanmechelen E, Uyttebroeck A, Van De Voorde A, Vanderstichele H: Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia; 2000 Dec;14(12):2076-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies.
  • Children acquire neuropsychologic dysfunctions after chemotherapy for hematologic malignancy.
  • In this study, putative changes in levels of CSF-tau (a marker of neural dysintegrity) in leukemic children prior to and during chemotherapy were studied.
  • Cerebrospinal fluid (CSF) samples were obtained before and during treatment from patients with B cell non-Hodgkin's lymphoma (NHL, n = 10), non-B cell acute lymphoblastic leukemia/NHL (non-B-ALL, n = 48), acute myeloid leukemia (AML, n = 9), other malignant diseases (n = 9), and six control children.
  • A sandwich-type ELISA (INNOTEST hTAU-Ag) was used for measuring CSF-tau.
  • The pre-induction treatment for non-B-ALL, consisting of only corticosteroids and methotrexate (MTX), resulted in a significant increase of tau at day 8 (on average to 535 pg/ml).
  • Larger increases as compared to baseline levels of CSF-tau were observed in patients treated for B-NHL with systemic vincristine, corticosteroids and cyclophosphamide, and intrathecal MTX (mean 776 pg/ml at day 8).
  • In two AML patients with CNS invasion, CSF-tau increased during chemotherapy up to 1,500 and 948 pg/ml, respectively.
  • In one non-B-ALL patient with MTX-induced clinical neurotoxicity, CSF-tau was above the detection limit of 2,000 pg/ml.
  • Almost one-third of the patients with hematological malignancies had elevated CSF-tau levels at diagnosis.
  • Transient high levels of CSF-tau, reaching levels observed in other neurodegenerative disorders, were observed during induction chemotherapy for non-B-ALL, B-NHL and CNS+ AML.
  • The clinical implications of both observations will be the subject of further study.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11187896.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / tau Proteins
  •  go-up   go-down


42. Phillips JA: Is Burkitt's lymphoma sexy enough? Lancet; 2006 Dec 23;368(9554):2251-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is Burkitt's lymphoma sexy enough?
  • [MeSH-major] Burkitt Lymphoma / mortality. Health Services Needs and Demand / statistics & numerical data. Poverty. Rural Health
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Africa South of the Sahara / epidemiology. Child. Cyclophosphamide / therapeutic use. Humans. Male


43. Nomura K, Fukumoto K, Shimizu D, Okuda T, Yoshida N, Kamitsuji Y, Matsumoto Y, Konishi H, Ueda Y, Horiike S, Okanoue T, Taniwaki M: Pseudomembranous colitis presenting as acute colonic obstruction without diarrhea in a patient with gastric Burkitt lymphoma. World J Gastroenterol; 2005 May 7;11(17):2681-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomembranous colitis presenting as acute colonic obstruction without diarrhea in a patient with gastric Burkitt lymphoma.
  • A 60-year-old man was hospitalized for chemotherapy for the treatment of Burkitt lymphoma of the stomach.
  • The patient became febrile and complained of crampy abdominal pain during the post-chemotherapy nadir.
  • Because stool cytotoxin assay for clostridium difficile was positive and colon fiberscopic examination showed a pseudomembrane at the left side of the colon, and a diagnosis of PMC was made.
  • Treatment with intracolonic vancomycin administration by colonoscopy and nasoileus tube was successful.
  • Physicians should take into account the possibility of bowel obstruction due to PMC occurring in patients undergoing chemotherapy and perform emergency colonoscopy examination of suspected cases.
  • [MeSH-major] Burkitt Lymphoma / complications. Enterocolitis, Pseudomembranous / diagnosis. Intestinal Obstruction / diagnosis. Stomach Neoplasms / complications
  • [MeSH-minor] Acute Disease. Colonoscopy. Diagnosis, Differential. Diarrhea. Humans. Male. Middle Aged


44. Shefet D, Robenshtock E, Paul M, Leibovici L: Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev; 2005;(2):CD004418
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial antibiotic treatment of CAP is usually empirical, customarily covering both typical and atypical pathogens.
  • OBJECTIVES: Assess the efficacy and need of adding antibiotic coverage for atypical pathogens in hospitalized patients with CAP, in terms of mortality and successful treatment.
  • SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005) which includes the Acute Respiratory Infection Group's specialized register; MEDLINE (January 1966 to January Week 2 2005); and EMBASE (January 1980 to January Week 2 2005).
  • There was no difference in mortality between the atypical arm and the non-atypical arm (RR 1.13; 95% CI 0.82 to 1.54).
  • The atypical arm showed an insignificant trend toward clinical success and a significant advantage to bacteriological eradication, which disappeared when evaluating methodologically high-quality studies alone.
  • Clinical success for the atypical arm was significantly higher for Legionella pneumophilae (L. pneumophilae) and non-significantly lower for pneumococcal pneumonia.
  • There was no significant difference between the groups in the frequency of (total) adverse events, or those requiring discontinuation of treatment.
  • However, gastrointestinal events were more common in the non-atypical arm (RR 0.73, 95% CI 0.54 to 0.99).
  • AUTHORS' CONCLUSIONS: No benefit of survival or clinical efficacy was shown to empirical atypical coverage in hospitalized patients with CAP.
  • This conclusion relates mostly to the comparison of quinolone monotherapy to non-atypical monotherapy.
  • Further trials, comparing beta-lactam (BL) or cephalosporin therapy to BL or cephalosporin combined with a macrolide in this population, using mortality as its primary outcome, should be performed.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antibiotic Prophylaxis. Pneumonia / drug therapy
  • [MeSH-minor] Adult. Community-Acquired Infections / drug therapy. Community-Acquired Infections / microbiology. Community-Acquired Infections / mortality. Humans. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2008;(1):CD004418 [18254049.001]
  • (PMID = 15846713.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 66
  •  go-up   go-down


45. Kim D, Ko Y, Suh Y, Koo H, Huh J, Lee W: Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea. Virchows Arch; 2005 Sep;447(3):593-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea.
  • To analyze the clinicopathologic characteristics of childhood non-Hodgkin's lymphoma (NHL) associated with Epstein-Barr virus (EBV), EBER in situ hybridization was performed in 80 cases of NHLs.
  • EBER-positive lymphomas account for 25% (20/80) and include NK/T-cell lymphoma (6/6), aggressive NK-cell leukemia (1/1), peripheral T cell lymphoma (5/11), diffuse large B-cell lymphoma (5/14), hydroa-like T-cell lymphoma (1/1), marginal zone B-cell lymphoma (1/2), and post-transplantation lymphoproliferative disorder (1/1).
  • Other types including 19 cases of Burkitt's lymphoma were negative.
  • Clinically, patients with EBV-positive B-cell lymphomas were cured with chemotherapy, whereas EBV-associated NK- and T cell lymphomas pursued fatal clinical course.
  • In conclusion, EBVs infected in childhood NHLs are frequently associated not only with NK- and T- cell lymphomas but also large B-cell lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Lymphoma, Non-Hodgkin / virology. Tumor Virus Infections / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Dec;91(12):1233-40 [11123421.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):427-42 [11594706.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Pathol Int. 2004 Mar;54(3):151-7 [14989737.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1695-704 [6697306.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):283-8 [9042791.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):121-8 [9210717.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4244 [14623773.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Histopathology. 1994 Feb;24(2):115-22 [8181803.001]
  • [Cites] Adv Cancer Res. 1993;62:179-239 [8109318.001]
  • [Cites] Blood Rev. 1993 Dec;7(4):215-22 [8130684.001]
  • [Cites] Leuk Lymphoma. 2001 Jan;40(3-4):405-11 [11426563.001]
  • (PMID = 15991005.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Viral Matrix Proteins; 0 / Viral Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


46. Oriol A, Ribera JM, Bergua J, Giménez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer; 2008 Jul 1;113(1):117-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
  • BACKGROUND: It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used.
  • The introduction of rituximab in BL therapeutic schemes has been scarcely explored.
  • The outcome and toxicity of HIV-positive patients with BL treated in a rituximab and intensive chemotherapy-based trial was evaluated.
  • METHODS: Thirty-six consecutive patients, 15 to 55 years of age, diagnosed with advanced stage BL were recruited from July 2003 to August 2006, stratified according to HIV infection status and treated with 6 cycles of intensive chemotherapy including 8 doses of rituximab.
  • Their clinical characteristics were comparable to those of the HIV-negative patients.
  • However, there were no statistically significant differences in 2-year overall survival (82%, 95% confidence interval [CI], 65%-99% and 73%, 95% CI, 54%-92%, respectively) or 2-year disease-free survival (93%, 95% CI, 82%-99% and 87%, 95% CI 72%-99%, respectively).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Drug Administration Schedule. Feasibility Studies. Female. Humans. Immunotherapy. Male. Middle Aged. Remission Induction. Rituximab. Survival Analysis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18457327.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


47. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Between February 2003 and June 2006, we evaluated 15 children with newly diagnosed NHL who were diagnosed and treated at the Pediatric Oncology Department of Hacettepe University.
  • Patients who were given chemotherapy previously or who received H. pylori eradication therapy were excluded from the study.
  • Pathologic diagnosis was made by examining the biopsy samples.
  • Twelve male and 3 female patients, with a median age of 7 (range: 3 to 16), were evaluated.
  • Six had stage IV characteristics, whereas another 9 patients had stage III disease.
  • Ten had high-grade B-cell lymphoma.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • The second one had anaplastic large cell lymphoma exclusively in abdominal lymph nodes.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • We did not find any positive test results in the other 12 patients with intestinal, stomach, or abdominal disease.
  • Preliminary results of our study suggest that H. pylori may not be the responsible agent for NHL involved the abdomen in childhood.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Lymphoma, B-Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Neoplasm Staging. Prospective Studies. Recurrence. Risk Assessment. Sampling Studies. Treatment Outcome. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


48. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphaël M, Terrier-Lacombe MJ, Société Française d'Oncologie Pédiatrique: The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood; 2001 Jun 1;97(11):3370-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
  • This study was undertaken to show that a high survival rate can be obtained in B-cell (Burkitt and large B-cell) lymphoma and L3 leukemia with multiagent chemotherapy adapted to the tumor burden (stage, resection status, percentage of blasts in bone marrow, and central nervous system [CNS] involvement) and early response to chemotherapy, to investigate actual prognostic factors, and to see if large B-cell lymphoma can be treated with the same regimen as Burkitt lymphoma.
  • Group B (patients not eligible for groups A or C) received 5 courses of chemotherapy with, in addition, high-dose methotrexate, 3 g/m(2) over 3 hours; infusional cytarabine; and intrathecal (IT) methotrexate.
  • Group C (patients with CNS involvement and acute lymphoblastic leukemia with at least 70% of blasts in bone marrow) received 8 courses with, in addition, high-dose methotrexate, 8 g/m(2); high-dose cytarabine; etoposide; and triple IT.
  • Except in group A, treatment started with a prephase (COP, low-dose vincristine and cyclophosphamide).
  • In group B, multivariate analysis of prognostic factors showed that a lactate dehydrogenase level more than 2-fold the normal value, no response after COP, and age of at least 15 years were associated with a lower EFS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Hydrocortisone / therapeutic use. Leucovorin / therapeutic use. Lymphoma, B-Cell / drug therapy. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11369626.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


49. He J, Chen ZX, Xue YQ, Pan JL, He HL, Li JQ, Wu YF, Huang YP, Zhu LL: [Study on clinical and biological characteristics of childhood acute leukemia with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):477-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on clinical and biological characteristics of childhood acute leukemia with MLL gene rearrangements].
  • OBJECTIVE: To study the clinical and laboratory features of childhood acute leukemia (AL) with MLL gene rearrangements.
  • METHODS: Sixteen of 298 cases of childhood AL with MLL rearrangements were studied by using MLL dual-color FISH, multiplex RT-PCR with 13 pairs of primers in combination with R banding karyotype analysis and cell immunophenotyping by flow cytometry.
  • Of these 16 patients, 8 received chemotherapy and 7 of them achieved complete remission, while the other 8 patients gave up treatment.
  • CONCLUSION: Multiplex RT-PCR combined with FISH provided a more accurate and sensitive method for detection of MLL gene rearrangements.
  • Finding out MLL gene rearrangement is of most importance in guiding therapy and predicting prognosis in childhood AL.
  • [MeSH-major] Gene Rearrangement. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383239.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


50. Gence A, Sahin C, Celayir AC, Yavuz H: Primary Burkitt lymphoma presenting as a solitary rectal polyp in a child. Pediatr Surg Int; 2008 Nov;24(11):1215-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma presenting as a solitary rectal polyp in a child.
  • Non-Hodgkin lymphoma (NHL) accounts for approximately 60% of all lymphomas in children and adolescents.
  • Primary rectal lymphoma in childhood is extremely rare.
  • Histopathological examination and immunohistochemistry study of the polyp revealed a high-grade B-cell lymphoma (Burkitt lymphoma).
  • These studies also showed lymphoma cells on the surgical border.
  • The patient was referred to pediatric oncology center for chemotherapy.
  • Primary rectal lymphoma in childhood is extremely rare; therefore, the possibility of malignancy in rectal polyps should be considered in the pediatric patients.
  • [MeSH-major] Burkitt Lymphoma / surgery. Intestinal Polyps / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 1989;19(6-7):474-6 [2771496.001]
  • [Cites] Arch Pediatr. 2002 Oct;9(10):1056-8 [12462838.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Pediatr Dev Pathol. 2003 Mar-Apr;6(2):182-6 [12522693.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Aug;31(2):193-4 [10941976.001]
  • [Cites] J Pediatr Surg. 1997 Jul;32(7):1004-8; discussion 1008-9 [9247222.001]
  • [Cites] J Pediatr Surg. 1990 Dec;25(12):1280-2 [2286908.001]
  • [Cites] Indian Pediatr. 1981 Nov;18(11):835-7 [7341479.001]
  • [Cites] Clin Radiol. 1994 Sep;49(9):594-600 [7955884.001]
  • (PMID = 18810465.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Thielen C, Herens C, Fassotte MF, Detrooz E, Drion P, Diss T, Boniver J, de Leval L: Establishment and characterisation of two novel human KSHV- and EBV-negative Burkitt cell lines, GAL-01 and GAL-02, from a primary lymphomatous effusion. Eur J Haematol; 2006 Oct;77(4):318-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterisation of two novel human KSHV- and EBV-negative Burkitt cell lines, GAL-01 and GAL-02, from a primary lymphomatous effusion.
  • OBJECTIVES: Burkitt's lymphoma (BL) is a highly aggressive mature B-cell neoplasm comprising endemic, sporadic and immunodeficiency-associated variants.
  • Human cell lines constitute a very useful tool to investigate the biology of lymphoid neoplasia.
  • In this study, we succeeded in establishing two human cell lines, GAL-01 and GAL-02, from a HIV-negative patient with Epstein-Barr virus (EBV) -negative sporadic BL presenting as an effusion.
  • GAL-01 and GAL-02 were established at diagnosis and after one course of polychemotherapy, respectively.
  • The in vivo effusion occurred in a very peculiar clinical setting; the patient having a previous history of intestinal diffuse large B-cell lymphoma.
  • METHODS: The morphologic, immunophenotypic and molecular genetic features of GAL cell lines are reported and compared with those of the parental tumour.
  • The findings clearly demonstrated that the Burkitt effusion did not represent disease progression of the intestinal tumour, but represented a second primary haematological malignancy.
  • RESULTS: Both cell lines were composed of medium-sized lymphoid cells with clumped chromatin, multiple medium-sized nucleoli and moderate amounts of vacuolated cytoplasm.
  • GAL cells display the phenotype and genotype of a B-cell lineage (positive for CD20, CD79a and clonal rearrangement of Ig heavy chain), carry the c-MYC rearrangement by t(8;22)(q24;q11) translocation and are characterised by the expression of the germinal centre-associated antigens CD10, BCL6, CD38 and absent to low BCL2 expression.
  • EBV and HHV8 were not identified within parental tumour or in cultured cells.
  • Subcutaneous injection of both cell lines to NOD/SCID mice induced tumour formation.
  • CONCLUSIONS: GAL-01 and GAL-02, two novel EBV-negative human BL cell lines represent a potentially useful experimental model to study the biology of BL possibly including the resistance to chemotherapy.
  • [MeSH-major] Lymphoma / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Chromosome Aberrations. Herpesvirus 4, Human / isolation & purification. Herpesvirus 6, Human / isolation & purification. Humans. Immunophenotyping. Karyotyping. Mice. Mice, Inbred NOD. Mice, SCID


52. Mailänder V, Gleisner B, Blau IW, Thiel E: Guillain-Barre-Strohl syndrome unraveled as paraneoplastic syndrome of B-cell acute lymphoblastic leukemia in a patient with preceding common variable immunodeficiency syndrome with Evans syndrome. Leuk Lymphoma; 2004 Jan;45(1):189-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guillain-Barre-Strohl syndrome unraveled as paraneoplastic syndrome of B-cell acute lymphoblastic leukemia in a patient with preceding common variable immunodeficiency syndrome with Evans syndrome.
  • A 26-year-old man with a history of common variable immunodeficiency and Evans syndrome (immunthrombocytopenia and immunhemolytic anemia) with sarcoid like lesions and lymph node enlargements in the previous history is described.
  • The patient presented with symptoms resembling Guillain-Barre-Strohl as paraneoplastic syndrome just before the diagnosis of acute lymphoblastic leukemia of the L3 type.
  • The patient was treated according to the B-ALL protocol of the German ALL study group and achieved a complete response after six cycles of chemotherapy together with a resolution of all neurologic symptoms.
  • [MeSH-major] Anemia / pathology. Burkitt Lymphoma / diagnosis. Immunologic Deficiency Syndromes / pathology. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Bone Marrow / pathology. Guillain-Barre Syndrome / diagnosis. Guillain-Barre Syndrome / immunology. Guillain-Barre Syndrome / pathology. Humans. Male. Tomography, X-Ray Computed


53. Matković S, Jelić S, Manojlović N, Milanović N: Non-Hodgkin's lymphomas with primary localization in large bowel and rectum. Med Sci Monit; 2000 Jan-Feb;6(1):68-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.
  • From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females.
  • In 3 patients an urgent laparotomy without previous diagnostic procedures was performed, while 4 patients had laparotomy only after radiographic and endoscopic diagnosis of a tumor.
  • Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic).
  • By further investigation, in 2 cases with localization within transversal part of colon and rectum no other sites of NHL were found.
  • They are under regular controls with 45+ and 45+ months disease free survival.
  • Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization.
  • Both patients had early death from lymphoma.
  • The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months.
  • Since the median survival in our group of patients is at the moment 41+ months and the median has not yet been reached, our experience does not confirm literature data claiming bad prognosis of primary NHL of the colon and rectum.
  • A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208286.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


54. Moran H, Yaniv I, Ashkenazi S, Schwartz M, Fisher S, Levy I: Risk factors for typhlitis in pediatric patients with cancer. J Pediatr Hematol Oncol; 2009 Sep;31(9):630-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was to define the epidemiologic and clinical features of typhlitis and to elucidate predisposing factors for its development.
  • The medical records of pediatric patients with cancer who were diagnosed with typhlitis from 1995 to 2005 were reviewed for clinical, laboratory, and imaging findings.
  • The results were compared with a group of patients with cancer but without typhlitis who were hospitalized during the same period.
  • The incidence was highest in patients with Burkitt's lymphoma (15%) and acute myeloblastic leukemia (12%).
  • Work-up included abdominal x-ray in all patients; abdominal ultrasonography and computed tomography were performed in 23% and 11% of patients, respectively.
  • No cases were missed by plain x-ray when compared with computed tomography and ultrasonography.
  • On multivariate analysis, mucositis [odds ratio (OR) = 30.7], stem cell transplantation (OR = 58.9), and receipt of chemotherapy in the previous 2 weeks (OR = 12.9) were significantly associated with the occurrence of typhlitis.
  • A high index of suspicion may be warranted in patients after stem cell transplantation or chemotherapy and patients with mucositis.
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bacteremia / complications. Bacteremia / epidemiology. Case-Control Studies. Child. Child, Preschool. Combined Modality Therapy. Diagnostic Imaging. Female. Hematopoietic Stem Cell Transplantation. Humans. Immunocompromised Host. Incidence. Infant. Israel / epidemiology. Length of Stay / statistics & numerical data. Male. Mucositis / chemically induced. Mucositis / epidemiology. Neutropenia / complications. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Postoperative Complications / etiology. Postoperative Complications / therapy. Recurrence. Retrospective Studies. Risk Factors. Single-Blind Method. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644402.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


55. Cerimele F, Battle T, Lynch R, Frank DA, Murad E, Cohen C, Macaron N, Sixbey J, Smith K, Watnick RS, Eliopoulos A, Shehata B, Arbiser JL: Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A; 2005 Jan 4;102(1):175-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.
  • Burkitt's lymphoma (BL) is an aggressive B cell neoplasm, which is one of the most common neoplasms of childhood.
  • In addition to being the first human neoplasm to be associated with EBV, BL is associated with a characteristic translocation, in which the Ig promoter is translocated to constitutively activate the c-myc oncogene.
  • Although many BLs respond well to chemotherapy, a significant fraction fails to respond to therapy, leading to death.
  • In this article, we demonstrate that EBV-positive BL expresses high levels of activated mitogen-activated protein kinase and reactive oxygen species (ROS), and that ROS directly regulate NF-kappaB activation.
  • Elevated reactive oxygen may play a role in diverse forms of viral carcinogenesis in humans, including cancers caused by EBV, hepatitis B, C, and human T cell lymphotropic virus.
  • Our findings imply that inhibition of ROS may be useful in the treatment of EBV-induced neoplasia.

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6 [9023347.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2899-916 [9205097.001]
  • [Cites] Am J Pathol. 1998 Apr;152(4):865-9 [9546345.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10106-11 [9707608.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3942-5 [9731506.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60 [10811897.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):709-13 [10826477.001]
  • [Cites] Clin Chim Acta. 2000 Oct;300(1-2):159-69 [10958872.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1937-45 [11106566.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):79-82 [11147680.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2171-7 [11360201.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):23077-83 [11304537.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42728-36 [11559697.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):715-20 [11805326.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] Mol Med. 2002 Jan;8(1):1-8 [11984000.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):1092-101 [12097418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1265-71 [12168936.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2612-9 [12171892.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1207-13 [12368194.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39456-62 [12177067.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3728-33 [12473582.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9790-5 [12514183.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1371-8 [14507645.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40778-87 [12909638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15595-600 [14673102.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):81-91 [15018892.001]
  • [Cites] Circ Res. 2004 May 14;94(9):1219-26 [15059930.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):47-56 [946170.001]
  • [Cites] Cell. 1979 Feb;16(2):313-22 [222455.001]
  • [Cites] Blood. 1986 Mar;67(3):612-5 [3004617.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):25-9 [3025109.001]
  • [Cites] J Exp Pathol. 1987 Summer;3(4):449-56 [2842477.001]
  • [Cites] J Virol. 1992 Nov;66(11):6288-93 [1404592.001]
  • [Cites] J Virol. 1993 Mar;67(3):1292-9 [8382295.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] J Virol. 1995 Feb;69(2):675-83 [7815530.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):529-35 [8627013.001]
  • (PMID = 15611471.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR042687; United States / NIAMS NIH HHS / AR / R01 AR047901; United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R01 AR 47901
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; 0 / Viral Proteins; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC544042
  •  go-up   go-down


56. Perkins AS, Friedberg JW: Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program; 2008;:341-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults.
  • This review will begin with a detail of the revision of the WHO classification, and pathological definitions of Burkitt lymphoma.
  • Over the past several years, molecular understanding of Burkitt lymphoma has improved significantly.
  • Using gene expression profiling, a genomic "signature" of Burkitt lymphoma may be identified, that has fidelity beyond c-myc expression, and the presence of the classical t(8;14).
  • Then, evaluation and therapy of the adult patient with Burkitt lymphoma will be reviewed.
  • Relatively few data exist on optimal therapy of the adult patient with Burkitt lymphoma.
  • Principles of therapy should include high doses of alkylating agents, frequent administration of chemotherapy, and attention to central nervous system (CNS) prophylaxis with high doses of systemic chemotherapy, intrathecal therapy, or both.
  • The outcome of adult patients with Burkitt lymphoma, particularly those over 40 years of age, is inferior to the outcome of younger patients, but may be improving over the past few years.
  • Results from an international collaborative effort, which are helpful in evaluating results of Burkitt lymphoma therapy in adults, will be presented.
  • HIV-associated Burkitt lymphoma, and elderly patients with Burkitt lymphoma, comprise special clinical situations that will be also covered in this review.

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074108.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


57. Troeger A, Schmitz I, Siepermann M, Glouchkova L, Gerdemann U, Janka-Schaub GE, Schulze-Osthoff K, Dilloo D: Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. Blood; 2007 Jul 1;110(1):384-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL.
  • Previous studies on apoptosis defects in acute lymphoblastic leukemia (ALL) have focused on chemotherapy-induced, primarily mitochondrial death pathways.
  • Here, we show that primary B-cell precursor ALL cells from children escape from receptor-dependent cell death in 2 ways: Resting ALL blasts are protected from receptor-mediated apoptosis due to the absence of CD95 surface expression.
  • Treatment with cycloheximide during CD40 activation prevents up-regulation of those c-FLIP isoforms and sensitizes ALL cells toward CD95-mediated apoptosis.
  • [MeSH-major] Antigens, CD40 / physiology. Antigens, CD95 / physiology. Apoptosis. CASP8 and FADD-Like Apoptosis Regulating Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376892.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Protein Isoforms
  •  go-up   go-down


58. Hartmann S, Hansmann ML: [Grayzone lymphoma. Clinical relevance]. Pathologe; 2010 Feb;31(1):42-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Grayzone lymphoma. Clinical relevance].
  • Malignant lymphomas are classified into different entities according to their morphology, immunohistochemical parameters and clinical behavior.
  • Several important pathogenetic events can be assigned to certain lymphoma entity types.
  • Nevertheless, some cases present overlapping morphologic and immunohistochemical characteristics and a clear-cut diagnosis cannot be made.
  • This is particularly the case with aggressive lymphomas for which a clear distinction cannot be made between the entities of diffuse large cell lymphoma/Burkitt lymphoma or primary mediastinal B cell lymphoma/classic Hodgkin's lymphoma.
  • Until further knowledge regarding the therapy, behavior and prognosis of these gray zone lymphomas has been gained, they should continue to be considered as distinct entities.
  • [MeSH-major] Lymphoma / classification. Lymphoma / pathology
  • [MeSH-minor] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. B-Lymphocytes / pathology. Biomarkers, Tumor / genetics. Burkitt Lymphoma / classification. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. DNA Mutational Analysis. Diagnosis, Differential. Hodgkin Disease / classification. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Immunoenzyme Techniques. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / classification. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. Molecular Diagnostic Techniques. Rituximab. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5573-9 [19786664.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2251-68 [18794340.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5494-502 [19706817.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] J Hematop. 2009 Jul;2(2):89-95 [19669187.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1318-26 [18641027.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):249-51 [15811621.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4503-6 [19734449.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2226-9 [18754028.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • (PMID = 20013122.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 37
  •  go-up   go-down


59. Gencosmanoglu R, Kurtkaya-Yapicier O, Tiftikci A, Avsar E, Tozun N, Oran ES: Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns of tetracycline or doxycycline-induced esophageal injury. J Clin Gastroenterol; 2004 Jul;38(6):484-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns of tetracycline or doxycycline-induced esophageal injury.
  • GOALS: The aims of this study are to describe 2 distinct clinical patterns of esophageal injury induced by tetracycline or its derivate doxycycline and to compare these patterns with respect to demographic, endoscopic, and clinical characteristics of the patients.
  • STUDY: Forty-eight patients with the diagnosis of doxycycline- or tetracycline-induced esophageal injury by endoscopy were analyzed retrospectively.
  • The patients were considered in 2 groups according to the type and the location of esophageal lesions (Group A: mid-esophageal ulceration, n = 18; Group B: distal esophagitis, n = 30).
  • In Group B, all patients had multiple micro-ulcerations in the distal esophagus.
  • Development of mid-esophageal ulceration was induced predominantly by doxycycline, whereas distal esophagitis was induced by tetracycline.
  • The description of drug ingestion with little or no water by patients in Group A was significantly more frequent than in Group B (94% vs. 10%, P < 0.001).
  • Prompt response to medical therapy was observed in both groups with no significant difference (P = 0.093).
  • CONCLUSIONS: The type of tetracyclines used by patients may give some clues to physicians on the pattern of esophageal injury because mid-esophageal ulceration seems to be more frequently associated with doxycycline and distal esophagitis with or without candidiasis with tetracycline.
  • [MeSH-minor] Adult. Age Distribution. Aged. Biopsy, Needle. Dose-Response Relationship, Drug. Esophagoscopy / methods. Esophagus / injuries. Esophagus / pathology. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Probability. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Hazardous Substances Data Bank. TETRACYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15220682.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] F8VB5M810T / Tetracycline; N12000U13O / Doxycycline
  •  go-up   go-down


60. Haytac MC, Antmen B, Dogan MC, Sasmaz I: Severe alveolar bone loss and gingival hyperplasia as initial manifestation of Burkitt cell type acute lymphoblastic leukemia. J Periodontol; 2003 Apr;74(4):547-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe alveolar bone loss and gingival hyperplasia as initial manifestation of Burkitt cell type acute lymphoblastic leukemia.
  • BACKGROUND: The purpose of this case report is to present severe alveolar bone destruction and gingival enlargement as initial manifestation of Burkitt cell type acute lymphoblastic leukemia (ALL-L3) in a 14-year-old boy.
  • METHODS: The patient was referred to the periodontology department with a 4-week history of gingival enlargement and loosening of teeth.
  • The clinical examination revealed gingival enlargement and expansion of alveolar mucosa particularly in molar regions of both jaws.
  • The results of blood tests and bone marrow aspiration were compatible with ALL-L3.
  • RESULTS: Remission-induction treatment with BFM-90 ALL chemotherapy protocol was started; however, the patient died 4 weeks after the diagnosis due to neutropenic sepsis.
  • The similarities of these findings with numb chin syndrome (NCS) and Burkitt's lymphoma (BL) are discussed in this report.
  • [MeSH-major] Alveolar Bone Loss / etiology. Burkitt Lymphoma / complications. Gingival Hyperplasia / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12747461.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Fayad L, Thomas D, Romaguera J: Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma; 2007 Dec;8 Suppl 2:S57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
  • Mantle cell lymphoma (MCL) and Burkitt lymphoma respond to initial intense therapies, such as hyper-CVAD (hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone) alternating with high-dose methotrexate/cytarabine, to which the monoclonal antibody rituximab has recently been added.
  • This report provides an update detailing the long-term outcome when this chemoimmunotherapy regimen is used as first-line therapy for newly diagnosed MCL, de novo Burkitt lymphoma, atypical Burkitt lymphoma, and mature B-cell acute lymphoblastic lymphoma (B-ALL).
  • Ninety-seven patients with de novo MCL and 31 patients with Burkitt lymphoma, atypical Burkitt lymphoma, and B-ALL were treated with rituximab plus hyper-CVAD alternating with rituximab/methotrexate/cytarabine under different institutional trials approved by the University of Texas M. D.
  • Overall RR for patients with Burkitt lymphoma/atypical Burkitt lymphoma/B-ALL was 97% (CR rate, 86%).
  • With a median follow-up of 22 months, the estimated 3-year OS, disease-free survival, and event-free survival rates were 89%, 88%, and 80%, respectively.
  • Rituximab plus hyper-CVAD alternating with rituximab/methotrexate/cytarabine is an effective dose-intense chemoimmunotherapy program for untreated MCL, Burkitt lymphoma, atypical Burkitt lymphoma, and B-ALL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Rituximab. Survival Rate. Texas. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284717.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


62. Lavu E, Morewaya J, Maraka R, Kiromat M, Ripa P, Vince J: Burkitt lymphoma in Papua New Guinea--40 years on. Ann Trop Paediatr; 2005 Sep;25(3):191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in Papua New Guinea--40 years on.
  • BACKGROUND: Burkitt lymphoma is common in tropical Africa and Papua New Guinea, where it has been reported to account for 16% of all childhood malignancies.
  • AIM: This study aimed to compare the geographical distribution of recent cases and their anatomical site of presentation with findings from previous studies, and to determine survival using the current treatment protocol.
  • METHODS: The study included all cases of Burkitt and Burkitt-like lymphoma in children up to 14 years of age diagnosed between January 1998 and December 2003.
  • RESULTS: Thirty-six children were diagnosed with Burkitt lymphoma, accounting for 50% of all lymphomas and 13% of all childhood malignancies.
  • Only two of the 16 patients who received chemotherapy were known to be in remission at 12 months.
  • CONCLUSIONS: Burkitt tumour remains a common childhood malignancy in PNG.
  • There is a need to improve diagnosis and reporting so that treatment can be started early.
  • The most appropriate treatment regimen for use in PNG and other resource-poor countries remains to be determined.
  • [MeSH-major] Burkitt Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156984.001).
  • [ISSN] 0272-4936
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Fasola FA, Shokunbi WA, Falade AG: Factors determining the outcome of management of patients with Burkitt's lymphoma at the University College Hospital Ibadan, Nigeria--an eleven year review. Niger Postgrad Med J; 2002 Sep;9(3):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors determining the outcome of management of patients with Burkitt's lymphoma at the University College Hospital Ibadan, Nigeria--an eleven year review.
  • In recent times, our experience in the chemotherapy of Burkitt's lymphoma patients in Ibadan, Nigeria has been that of poor outcome, hence this study was undertaken to determine the factors leading to the poor results of chemotherapy of Burkitt s lymphoma in Ibadan.
  • A retrospective analysis of Burkitt s Lymphoma patients seen over eleven year period, between January 1987 to December 1997 at the Paediatrics and Haematology Departments of the University College Hospital, Ibadan was carried out.
  • Majority of the patients (76.2%) were stage D, only 4.5% were stages A and of the 67 patients, only 57 (83.6%) had chemotherapy, 40 of whom had COAP, 8 had COMP and 9 patients had either cyclophosphamide or cytosar as monotherapy.
  • Only 22.8% of patients that received chemotherapy went into complete remission.
  • In this study, we observed a declining overall complete remission rate of 22.8% (compared to 47% in 1979) in Burkitt s Lymphoma patients.
  • The presence of large amount of fake drugs in the Nigerian market may imply that some of the cytotoxic drugs used in these patients could have been fake drugs.
  • We suggest that the government should subsidize the therapy of these patients as well as eradicate the presence of fake drugs in the market, thereby increasing the chances of a cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Child. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Drug and Narcotic Control. Female. Humans. Male. Neoplasm Staging. Nigeria / epidemiology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12501276.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


64. Riccio B, Mato A, Olson EM, Berns JS, Luger S: Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther; 2006 Dec;5(12):1614-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature.
  • Spontaneous tumor lysis syndrome (TLS) is a constellation of electrolyte abnormalities and acute renal failure, which occurs in the setting of rapid cell turnover prior to the administration of cytotoxic chemotherapy.
  • While spontaneous TLS is well described in patients with Burkitt's lymphoma, it is thought to occur less commonly in other hematologic malignancies.
  • We present two cases of spontaneous TLS in patients with newly diagnosed acute myeloid leukemia (AML) followed by a review of the literature in this field.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Tumor Lysis Syndrome / complications
  • [MeSH-minor] Aged. Blood Urea Nitrogen. Burkitt Lymphoma / complications. Creatinine / blood. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204864.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  • [Number-of-references] 45
  •  go-up   go-down


65. Kagu MB, Ahmed SG, Bukar AA: Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review. Afr J Med Med Sci; 2005 Dec;34(4):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review.
  • Pre-treatment tumour lysis syndrome (pre-TTLS) is not an unusual clinical entity in high-grade lymphomas and lymphoblastic leukaemias.
  • The overall incidence and frequency is unknown and to the best of our knowledge none has been published in Nigeria involving adult females with advanced stage Burkitt's lymphoma (ASBL).
  • Three of the reported cases had pre-TTLS complicated by acute renal failure (ARF).
  • The first two cases had a complete reversal of the ARF with aggressive supportive management and slow introduction of cytotoxic chemotherapy whereas the third case died of ARF due to delay in commencement of aggressive supportive management, chemotherapy and haemodialysis due to financial constraint.
  • This paper stresses the importance of aggressive supportive management and slow introduction of cytotoxic chemotherapy in patients with a stage C and/or stage D Burkitt's lymphoma presenting with pre-TTLS.
  • [MeSH-major] Burkitt Lymphoma / complications. Renal Insufficiency / etiology. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Fatal Outcome. Female. Humans. Nigeria. Risk Assessment. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752673.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


66. Henrich S, Gez S, Crossett B, Mulligan SP, Christopherson RI: Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides Nucleotides Nucleic Acids; 2008 Jun;27(6):634-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
  • The purine analog fludarabine (FdAMP) is widely used for chemotherapy of B-lymphoid malignancies, and multiple mechanisms of action leading to apoptosis have been proposed.
  • We examined changes at the protein level induced in the Raji cell line (Burkitt's lymphoma) by fludarabine nucleoside (FdA).
  • FdA thus induces changes in the genetic program of the cells that might be exploited to obtain synergy with therapeutic antibodies.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Leukemia / metabolism. Lymphoma / metabolism. Tumor Suppressor Protein p53 / metabolism. Vidarabine / analogs & derivatives
  • [MeSH-minor] Animals. Antibodies / metabolism. Antibodies / therapeutic use. Antigens, CD / metabolism. Apoptosis / drug effects. Cattle. Cell Line, Tumor. Drug Synergism. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18600519.001).
  • [ISSN] 1532-2335
  • [Journal-full-title] Nucleosides, nucleotides & nucleic acids
  • [ISO-abbreviation] Nucleosides Nucleotides Nucleic Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / Tumor Suppressor Protein p53; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


67. Tillie-Leblond I, Gosset P, Tonnel AB: Inflammatory events in severe acute asthma. Allergy; 2005 Jan;60(1):23-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory events in severe acute asthma.
  • Severe acute asthma can be induced by different triggers, allergens, irritants, viruses, etc., which induce inflammation and provoke acute bronchoconstriction.
  • Inflammatory cells, such as activated eosinophils and neutrophils identified in sputum and bronchial lavages (BL) in severe acute asthma from children and adults are associated with increased levels of IL-5, IL-8, and of proinflammatory mediators.
  • Together, these inflammatory mediators are responsible for the diffuse bronchial inflammation, which involve large and small airways.
  • An aberrant CD8+ T lymphocyte response in bronchi, with a cytotoxic activity has been associated with fatal asthma.
  • Moreover, the persistence of inflammatory cells in bronchi, particularly neutrophils, which respond poorly to corticosteroids, could be in part responsible for the epithelial damage, the extensive mucus plugging, and the abnormalities of epithelial and endothelial permeability which are associated with severe acute asthma.
  • [MeSH-minor] Acute Disease. Adrenal Cortex Hormones / therapeutic use. Drug Resistance. Humans. Severity of Illness Index. Status Asthmaticus / complications. Status Asthmaticus / drug therapy

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Acute Bronchitis.
  • MedlinePlus Health Information. consumer health - Asthma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575926.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 53
  •  go-up   go-down


68. Mitsudo K, Tohnai I, Hayashi Y, Ueda M, Yambe M, Hirose Y: A case of Burkitt's lymphoma that presented initially with resorption of alveolar bone. Oral Dis; 2000 Jul;6(4):256-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Burkitt's lymphoma that presented initially with resorption of alveolar bone.
  • However, no tumor mass was seen.
  • Accordingly, he was diagnosed as Burkitt's lymphoma, and received intensive chemotherapy which relieved his symptoms and decreased his tumor.
  • However, his disease soon became refractory to chemotherapy, and he died 11 weeks after the onset.
  • [MeSH-major] Alveolar Bone Loss / etiology. Burkitt Lymphoma / complications. Jaw Neoplasms / complications
  • [MeSH-minor] Adolescent. Antigens, CD19 / analysis. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Fatal Outcome. Follow-Up Studies. Gingival Diseases / etiology. HLA Antigens / analysis. Humans. Male. Neprilysin / analysis. Tooth Mobility / etiology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10918565.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / HLA Antigens; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


69. Coutsouvelis J, Corallo CE: The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia. J Oncol Pharm Pract; 2009 Jun;15(2):107-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia.
  • BACKGROUND: Patients diagnosed with Acute Myeloid Leukaemia (AML) often receive cytarabine-based chemotherapy as standard treatment.
  • Such treatments are known to cause hepatic dysfunction characterized by a combination of jaundice, hyperbilirubinemia and increases in liver enzymes.
  • AIM: To report a case of isolated hyperbilirubinemia in a patient treated with cytarabine-based chemotherapy for AML.
  • CLINICAL DETAILS: After a diagnosis of AML the patient was admitted to hospital to receive induction chemotherapy consisting of high-dose cytarabine, idarubicin, and etoposide.
  • The chemotherapy was delivered over 7 days, and on the eighth day the patient had a bilirubin (BL) level of 27 micromol/L(normal range 522 micromol/L).
  • This isolated hyperbilirubinemia remained for the rest of the patient's admission, peaking on day 26, with a level of 255 micromol/L.
  • After a stay in the intensive care unit, the patient was discharged on day 45 with a bilirubin level of 33 micromol/L.
  • OUTCOME: The isolated hyperbilirubinemia resolved slowly and on day 68, when the patient was re-admitted for further dose-reduced cytarabine, the BL level was 21 micromol/L.
  • A lower dose of cytarabine for future treatment should be considered.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytarabine / adverse effects. Hyperbilirubinemia / chemically induced. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Etoposide / administration & dosage. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Jaundice.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818219.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


70. Jabbour E, Ribrag V: [Acute tumor lysis syndrome: update on therapy]. Rev Med Interne; 2005 Jan;26(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute tumor lysis syndrome: update on therapy].
  • [Transliterated title] Traitement actuel du syndrome de lyse tumorale.
  • PURPOSE: The tumor lysis syndrome (TLS) is a set of complications that can arise from treatment of high burden, drug sensitive and rapidly proliferating neoplasm particularly of hematological origin.
  • This syndrome can be observed before any treatment because of spontaneous tumoral cellular death, and is generally worsened when chemotherapy is initiated.
  • CURRENT KNOWLEDGE AND KEY POINTS: Although TLS is primarily observed during therapy of acute leukemia, Burkitt's lymphomas and lymphoblastic lymphomas, it can also be observed in other hematological malignancies and during the treatment of rare solid tumors.
  • The early management of TLS can, indeed, have an impact on the global therapy of these patients who need to be treated with high-dose anti-cancer agents with renal elimination.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15639323.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.7.3.3 / Urate Oxidase
  • [Number-of-references] 25
  •  go-up   go-down


71. Zuo YX, Zhang LP, Lu AD, Wang B, Liu GL: [Clinical characteristics of children with B cell type acute lymphoblastic leukemia carrying different fusion gene]. Zhongguo Dang Dai Er Ke Za Zhi; 2010 Mar;12(3):172-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of children with B cell type acute lymphoblastic leukemia carrying different fusion gene].
  • OBJECTIVE: To investigate whether there were differences in the clinical characteristics, cytogenetic characteristics, immunophenotype and prognosis in children with B cell type acute lymphoblastic leukemia (B-ALL) carrying different fusion genes.
  • METHODS: The research included 80 children with B-ALL from Peking University People's Hospital between March 2006 and December 2008.
  • Data including clinical characteristics, morphology, immunophenotype and cytogenetic characteristics were collected, and the disease-free survival (DFS) was evaluated.
  • They had low tumor load.
  • FAB-L2 morphology was commonly observed, but t(12;21) was often absence in these children.
  • Up to now,17 children who survived were disease-free.
  • Thirteen children showed FAB-L1 morphology.
  • In the 11 children with BCR/ABL+B-ALL, 10 children showed common B type immunophenotype.
  • FAB-L1 and FAB-L2 morphology was found in 4 children respectively.
  • Two children with MLL/AF4 positive B-ALL had high tumor load.
  • Their morphologic diagnosis was FAB-L1.
  • One child discontinued treatment at the early stage of chemotherapy, and the other child survived disease-free until now.
  • CONCLUSIONS: The B-ALL children with different fusion genes have different clinical characteristics, immunophenotypes and prognosis.
  • [MeSH-major] Gene Fusion. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Female. Homeodomain Proteins / genetics. Humans. Immunophenotyping. Infant. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350423.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


72. Granov AM, Rozenberg OA, Tsybul'kin EK, Erokhin VV, Khubulava GG, Likhvantsev VV, Osovskikh VV, Bautin AE, Gavrilin SV, Kazennov VV, Zhilin IuN, Nabokova TS, Shefer SP, Vashkevich SM, Nefedov AV, Seĭliev AA, Volchkov VA: [Critical state medicine. Surfactant therapy of adult respiratory distress syndrome (results of multicenter studies)]. Vestn Ross Akad Med Nauk; 2001;(5):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Critical state medicine. Surfactant therapy of adult respiratory distress syndrome (results of multicenter studies)].
  • [Transliterated title] Meditsina kriticheskikh sostoianiĭ. Surfaktant-terapiia respiratornogo distress-sindroma vzroslykh (rezul'taty mnogotsentrovykh ispytaniĭ).
  • The paper provides evidence for the pathogenetic approach to treating acute lung lesion (ALL) and adult respiratory distress syndrome (ARDS).
  • An algorithm of the use of Russian lung surfactant preparations: CT-HL and CT-BL has been developed.
  • In involves earlier (the first days following the onset of respiratory failure) use of surfactant, its combined bolus intratracheal or intrabronchial administration in doses of 200-400 mg/m2, followed by continuous (5-day) aerosol inhalation in doses of 20-30 mg/h for children and 30-75 mg/h for adults until pronounced clinical and X-ray effects are shown.
  • Earlier use of the drugs made it possible to transfer patients to safe AV regimens and to eliminate ALL and ARDS rapidly and to significantly reduce mortality due to critical states.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11510148.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Pulmonary Surfactants
  •  go-up   go-down


73. Reiter A, Klapper W: Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol; 2008 Jul;142(3):329-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
  • Diffuse large B-cell lymphomas (DLBCL) are neoplasms of transformed mature B cells, accounting for approximately 10% of non-Hodgkin lymphomas (NHL) of childhood.
  • Clinical features of children with DLBCL differ from those with other NHL entities, e.g. by a lower frequency of bone-marrow and central nervous system involvement.
  • Treatment strategies originally designed for Burkitt lymphoma appear to be efficacious for children with DLBCL.
  • However, children with primary mediastinal large B-cell lymphoma may need a more specific treatment approach, given their inferior outcome in recent studies.
  • The addition of the monoclonal anti-CD20 antibody rituximab to standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome of adults with DLBCL significantly.
  • However, preliminary data suggest differences between DLBCL of children and adults concerning cell of origin, genetic abnormalities and responsiveness to current treatments.
  • Thus, the potential role of monoclonal antibodies in the treatment of children with DLBCL remains to be determined.
  • Furthermore, these tools may enable a more risk-adapted and rationally targeted subtype-specific therapy in the future.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Clinical Trials as Topic. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Humans. Immunophenotyping. Lymph Nodes / immunology. Prednisone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537979.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 102
  •  go-up   go-down


74. Mimura N, Tsujimura H, Ise M, Sakai C, Takagi T, Nagata M, Kumagai K: Therapy-related leukemia following chemoradiotherapy for esophageal cancer. Eur J Haematol; 2010 Oct;85(4):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related leukemia following chemoradiotherapy for esophageal cancer.
  • Although a sufficiently long-time survival has resulted in the increase of several treatment-related late toxicities, little is still known about the incidence of secondary malignancies.
  • In our hospital, 348 patients with esophageal cancer received chemotherapy consisting of nedaplatin and 5-fluorouracil and concurrent irradiation.
  • Four patients developed leukemia after 19-48 months of follow-up.
  • Two patients were diagnosed with overt leukemia from myelodysplastic syndrome presenting a complex karyotype, including the deletion of chromosome 5 or 7.
  • Notably, one patient showed an additional chromosomal abnormality with t(9;22)(q34;q11).
  • Other patients developed acute myeloid leukemia with t(9;22)(q34;q11) and Burkitt leukemia with t(8;14)(q24;q32).
  • All patients eventually succumbed to leukemia.
  • Our report supports the idea that the concurrent administration of radiotherapy with these agents affects the risk of leukemia.
  • Interestingly, rare balanced chromosomal abnormalities were observed in the present cases, thus providing new insights into the leukemogenesis of therapy-related leukemia.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Leukemia, Myeloid, Acute. Myelodysplastic Syndromes. Neoplasms, Second Primary
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Chromosome Aberrations / chemically induced. Chromosomes, Human, Pair 5. Combined Modality Therapy / adverse effects. Female. Fluorouracil / administration & dosage. Humans. Karyotyping. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Radiotherapy / adverse effects


75. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E: Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma; 2008;49 Suppl 1:52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.
  • The recurrence of non-Hodgkin lymphoma (NHL) in the central nervous system (CNS) is rapidly fatal in most cases.
  • Highly aggressive lymphomas, such as lymphoblastic and Burkitt lymphomas, carry a high risk of CNS relapse.
  • CNS relapse in intermediately aggressive subtypes, such as diffuse large B-cell lymphoma, is uncommon, but not rare.
  • The risk of CNS relapse in indolent lymphomas is low.
  • Prognostic markers of CNS relapse include elevated serum lactate dehydrogenase levels, the presence of B symptoms, and extranodal involvement at more than one site.
  • Most centers give prophylactic CNS chemotherapy to patients considered at high risk of CNS recurrence.
  • More research is needed to define which patients might benefit from CNS prophylaxis at initial treatment and to find the optimal regimen for prophylaxis.
  • A variety of treatments have been used to treat CNS relapse, but current regimens have had little success in extending survival after CNS relapse.
  • Although long-term survival has been reported in a minority of patients with isolated CNS recurrence after treatment with methotrexate, more effective regimens are needed if survival times after relapse are to be prolonged.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Lymphoma / drug therapy. Premedication / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18821433.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  •  go-up   go-down


76. Nomura Y, Yoshida S, Karube K, Takeshita M, Hirose S, Nakamura S, Yoshino T, Kikuchi M, Ohshima K: Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Sci; 2008 Aug;99(8):1564-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma.
  • Burkitt's lymphoma and atypical Burkitt/Burkitt-like lymphoma (BL/BLL) are considered highly aggressive B-cell lymphomas with a rapid proliferative rate and high rate of apoptosis.
  • The aim of the present study was to confirm whether apoptotic and cell proliferative factors affect BL/BLL clinical outcomes.
  • We retrospectively analyzed the relationship between the clinical and immunophenotypic features of 43 BL/BLL patients by immunohistochemical staining for bcl-2 and double staining for Ki-67 plus caspase-3.
  • The 43 BL/BLL patients were divided into high caspase-3 (n = 19) and low caspase-3 (n = 24) groups.
  • There was a significant difference in the overall survival between the high (77%) and low caspase-3 (33%) groups; the survival rate of patients in the low caspase-3 group who received aggressive short-term chemotherapy (58%) was significantly better than that of patients who received cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) therapy (17%).
  • We suggest that caspase-3 may function as an indicator of the prognosis of BL/BLL.
  • [MeSH-major] Biomarkers, Tumor. Burkitt Lymphoma / genetics. Caspase 3 / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / genetics. Cell Proliferation. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Expression. Genes, bcl-2 / genetics. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754867.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.22.- / Caspase 3; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. Greenwood MJ, Dodds AJ, Garricik R, Rodriguez M: Posterior leukoencephalopathy in association with the tumour lysis syndrome in acute lymphoblastic leukaemia--a case with clinicopathological correlation. Leuk Lymphoma; 2003 Apr;44(4):719-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior leukoencephalopathy in association with the tumour lysis syndrome in acute lymphoblastic leukaemia--a case with clinicopathological correlation.
  • We report a case and autopsy findings of posterior leukoencephalopathy (PL) developing during induction chemotherapy for B-cell acute lymphoblastic leukaemia (B-ALL) complicated by tumour lysis syndrome.
  • Only rare cases of PL developing during treatment for haematological malignancy have been reported and to our knowledge it has not been previously reported in association with tumour lysis syndrome.
  • [MeSH-major] Neuromuscular Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tumor Lysis Syndrome / complications

  • MedlinePlus Health Information. consumer health - Neuromuscular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12774751.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Owen SM, Rudolph D, Wang W, Cole AM, Sherman MA, Waring AJ, Lehrer RI, Lal RB: A theta-defensin composed exclusively of D-amino acids is active against HIV-1. J Pept Res; 2004 Jun;63(6):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A theta-defensin composed exclusively of D-amino acids is active against HIV-1.
  • Theta-defensins composed of L-amino acids are likely to be unstable in environments that contain host and microbial proteases.
  • Although these peptides have identical sequences, RC-112 is composed exclusively of D-amino acids, whereas retrocyclin-1 contains only L-amino acids.
  • We compared the ability of these peptides to protect JC53-BL human cells from infection by 30 primary HIV-1 isolates.
  • JC53-BL cells are modified HeLa cells that express surface CD4, CXCR4, and CCR5.
  • The superior antiviral performance of RC-112 most likely reflected its resistance to degradation by surface-associated or secreted proteases of the JC53-BL target cells.
  • Theta-defensins composed exclusively of D-amino acids merit consideration as starting points for designing microbicides for topical application to the vagina or rectum.
  • [MeSH-major] Defensins / chemistry. Defensins / pharmacology. HIV-1 / drug effects
  • [MeSH-minor] Amino Acids / chemistry. Animals. Anti-HIV Agents / pharmacology. HIV Infections / drug therapy. Humans. Stereoisomerism

  • Genetic Alliance. consumer health - HIV.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175019.001).
  • [ISSN] 1397-002X
  • [Journal-full-title] The journal of peptide research : official journal of the American Peptide Society
  • [ISO-abbreviation] J. Pept. Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 056921; United States / NIAID NIH HHS / AI / AI 22839; United States / NIAID NIH HHS / AI / AI 37945; United States / NIAID NIH HHS / AI / AI 52017
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Anti-HIV Agents; 0 / Defensins; 0 / theta-defensin
  •  go-up   go-down


79. Kurosawa H, Matsunaga T, Shimaoka H, Sato Y, Kuwashima S, Sugita K, Hagane K, Eguchi M: Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction. J Pediatr Hematol Oncol; 2002 May;24(4):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction.
  • Large gastric folds in adults are seen in many benign and malignant conditions, but they are rare in children with malignant diseases such as non-Hodgkin lymphoma.
  • The authors report a patient with non-Hodgkin lymphoma who had large gastric folds and jaundice as the initial symptoms.
  • Magnetic resonance imaging showed a typical diffuse infiltrating type of pancreatic lymphoma.
  • Because complete bilateral lower limb paralysis developed as a result of the epidural soft tissue mass, laminectomy and tumor resection were performed and a diagnosis of disseminated Burkitt lymphoma was established.
  • After completing 6 months of chemotherapy, the patient has been disease-free without neurologic complications for 2.5 years.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cholestasis / diagnosis. Gastric Mucosa / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972102.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Saha R, Jain S, Naithani R, Kapoor G: Chemotherapy-induced palmoplantar erythrodysesthesia in a child with Burkitt lymphoma. Pediatr Blood Cancer; 2009 Oct;53(4):682
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced palmoplantar erythrodysesthesia in a child with Burkitt lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Burkitt Lymphoma / drug therapy. Cytarabine / adverse effects. Etoposide / adverse effects. Foot Dermatoses / chemically induced. Hand Dermatoses / chemically induced. Paresthesia / chemically induced

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489054.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


81. Wen BL, Zhou H, Liu BY, Sun GJ, Liu WH, Peng J, Hu JQ, He LY, Fang YG, Zi MJ: [Analysis on acupoint prescription for acupoint sticking therapy of treating winter diseases in summer for preventing and curing chronic cough and asthma]. Zhongguo Zhen Jiu; 2010 Aug;30(8):647-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on acupoint prescription for acupoint sticking therapy of treating winter diseases in summer for preventing and curing chronic cough and asthma].
  • Based on ZhangShi YiTong written by ZHANG Lu of Qing dynasty, and the record that external application of Baijiezi (seeds of Brassica Alba) for treating asthma of cold syndrome, retrospective study is conducted to modern literature of treating winter diseases in summer with acupoint sticking therapy for preventing and treating chronic cough and asthma.
  • The results show that the top ten common acupoints used for acupoint sticking therapy of treating winter diseases in summer are Feishu (BL 13), Dingchuan (EX-B 1), Xinshu (BL 15), Geshu (BL 17), Danzhong (CV 17), Shenshu (BL 23), Gaohuang (BL 43), Dazhui (GV 14), Pishu (BL 20), Tiantu (CV 22), most of which belong to the Bladder Meridian of Foot-Taiyang, Conception Vessel and Governor Vessel or extra-meridian points.
  • It refers that the core acupoints of acupoint sticking therapy are Feishu (BL 13), Dingchuan (EX-B 1), Xinshu (BL 15), Geshu (BL 17), Danzhong (CV 17), and adjunct points can be selected by syndrome, disease different stage, disease or symptoms.
  • [MeSH-major] Acupuncture Points. Asthma / prevention & control. Cough / prevention & control. Drugs, Chinese Herbal / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Drug Prescriptions. Humans. Seasons

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Cough.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942281.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


82. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens.
  • METHODS: To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B-ALL, 31 patients with newly diagnosed BL or B-ALL received the hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen with rituximab.
  • RESULTS: Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease.
  • The 3-year overall survival (OS), event-free survival, and disease-free survival rates were 89%, 80%, and 88%, respectively.
  • Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3-year OS rate of 89%.
  • Multivariate analysis of current and historical (those treated with hyper-CVAD alone) groups identified age and treatment with rituximab as favorable factors.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Immunotherapy. Infusions, Intravenous. Male. Middle Aged. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage


83. Perkins SL, Lones MA, Davenport V, Cairo MS: B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report. Clin Adv Hematol Oncol; 2003 May;1(5):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report.
  • Paraffin-embedded diagnostic biopsy materials from a large cohort of pediatric and adolescent patients with mature B-cell non-Hodgkin's lymphoma (NHL) treated on the Children's Cancer Group arm of an international cooperative trial were studied to determine their phenotypic features and the feasibility of using targeted bioimmune therapies.
  • There were 345 patients eligible for analysis: 208 with Burkitt's lymphoma (BL), 43 with high-grade B-cell lymphoma, Burkitt-like (HGBL), and 94 with diffuse large B-cell lymphoma (DLBCL).
  • Immunophenotypic studies showed positive staining with CD20 in 100% of cases of BL and HGBL and in 98% of cases with DLBCL.
  • CD22 expression was present in all cases of BL and DLBCL and in 87% of cases HGBL.
  • This study indicates that immune-based therapies such as rituximab and ibritumomab-tiuxetan (anti-CD20) and epratuzumab (anti-CD22) are feasible in pediatric cases of mature B-cell NHLs.
  • [MeSH-major] Antigens, Neoplasm / analysis. Drug Delivery Systems. Lymphoma, B-Cell / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224429.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Surface
  •  go-up   go-down


84. Mowafi F, Cagigi A, Matskova L, Björk O, Chiodi F, Nilsson A: Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation. Pediatr Blood Cancer; 2008 Apr;50(4):812-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: CXCL12 (SDF-1alpha) is a chemokine, which plays an important role in normal B-cell lymphopoesis, migration and homing to the bone marrow (BM) and previous studies have suggested a role for CXCL12 and its receptor CXCR4 in the pathogenesis of ALL.
  • Signalling via the CXCL12/CXCR4 axis was further characterized in an in vitro model using the pre-B leukaemic cell line Nalm-6.
  • RESULTS: The serum level of CXCL12 in children at diagnosis of pre-B-ALL is significantly higher than in healthy children (4.8 (0-32) ng/ml vs. 0 (0-3.2) ng/ml, P < 0.001).
  • After completed chemotherapy, CXCL12 decreases to levels comparable to those found in the control group.
  • In addition, we found that recombinant CXCL12 enhances pre-B leukaemic cell proliferation in vitro.
  • The CXCL12/CXCR4 axis is able to initiate functional signalling and we show that STAT5 is activated in CD19+ leukaemic cells from BM of ALL patients and in the leukaemic cell line Nalm-6.
  • CONCLUSION: Our findings suggest that CXCL12 may have a role in leukaemic cell proliferation and survival during childhood ALL.
  • [MeSH-major] Cell Proliferation. Chemokine CXCL12 / blood. Chemokine CXCL12 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. STAT5 Transcription Factor / metabolism
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Enzyme Activation / physiology. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Immunohistochemistry. Infant. Male. Precursor Cells, B-Lymphoid / pathology. Receptors, CXCR4 / metabolism. Recombinant Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17914737.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4; 0 / Recombinant Proteins; 0 / STAT5 Transcription Factor
  •  go-up   go-down


85. Manolopoulos L, Nikolopoulos TP, Yiotakis J, Karapatsas J, Maris A, Ferekidis E: Burkitt's lymphoma in the base of the tongue: differential diagnosis and management. ORL J Otorhinolaryngol Relat Spec; 2003 Jul-Aug;65(4):226-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in the base of the tongue: differential diagnosis and management.
  • Burkitt's lymphoma is the most common malignancy in African children but can occur sporadically in every country.
  • However, complex chemotherapy regimens can now cure approximately 50-80% of adult patients with Burkitt's lymphoma or small noncleaved lymphoma, and in pediatric populations the cure rate is even higher.
  • Although the African type has a preference to the head and neck region (whereas the sporadic type to the abdomen), involvement of the base of the tongue is extremely rare as only 1 case has ever been reported in the English literature.
  • The present study describes a patient with Burkitt's lymphoma presenting as a single mass in the base of the tongue without any abdominal or other extra-abdominal involvement.
  • The patient was submitted to chemotherapy (intravenous and intrathecal) and skull radiotherapy.
  • Today, 17 months after the diagnosis, the patient is disease free.
  • Physicians should be aware of the extranodal manifestations of Burkitt's lymphoma and their differential diagnosis in order to achieve early diagnosis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Tongue Neoplasms / diagnosis. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14564099.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


86. Lin P, Jones D, Dorfman DM, Medeiros LJ: Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol; 2000 Nov;24(11):1480-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement.
  • Precursor B-cell lymphoblastic lymphoma (B-LBL) is uncommon and accounts for less than 10% of cases of lymphoblastic lymphoma.
  • We collected 25 cases of B-LBL, occurring in children and adults, and report the clinical and histologic features.
  • Patients with concurrent precursor B-cell acute lymphoblastic leukemia (B-ALL) or a history thereof were excluded.
  • There was no evidence of bone marrow disease at the time of diagnosis in 23 patients; two patients had focal (<5%) involvement.
  • The treatment and survival data available for a subset of patients with B-LBL were compared with those from a series of patients with B-ALL at our institution.
  • The primary sites of disease were skin (nine cases), bones (five cases), soft tissue (four cases), lymph nodes, (three cases), breast (two cases), stomach and colon (one case), and mediastinum (one case).
  • Clinical stage was stage I in 13 cases, stage II in seven cases, stage III in three cases, and stage IV in two cases.
  • Histologically, each neoplasm was diffuse and composed of small to medium-sized lymphoid cells with blastic nuclear chromatin and a high mitotic rate.
  • All cases were positive for B-cell antigens and terminal deoxynucleotidyl transferase.
  • Of 14 patients with available survival data, all achieved complete clinical response after combination chemotherapy (13 patients) or surgical excision followed by local irradiation (one patient).
  • Five (35.7%) patients subsequently relapsed, including the patient who had received only irradiation, and four of these patients died after a median survival time of 60 months.
  • None of the patients had leukemia, although one patient developed extensive bone marrow involvement.
  • Unlike precursor T-cell lymphoblastic lymphoma, which commonly involves lymph nodes and the mediastinum, B-LBL usually involves extranodal sites, most often the skin, and rarely presents as a mediastinal mass.
  • With aggressive chemotherapy, patients with precursor B-LBL rarely develop leukemia and appear to have a better prognosis than do patients with B-ALL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Precancerous Conditions / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Bone Marrow / pathology. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Flow Cytometry. Follow-Up Studies. Humans. Immunoenzyme Techniques. Immunophenotyping. In Situ Nick-End Labeling. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


87. Moore S, Suttle J, Bain S, Story C, Rice M: Acute lymphoblastic leukemia characterized by t(8;14)(q11.2;q32). Cancer Genet Cytogenet; 2003 Feb;141(1):1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia characterized by t(8;14)(q11.2;q32).
  • The t(8;14)(q11.2;q32) is emerging as an uncommon, though recurrent cytogenetic finding.
  • As of yet, too few cases of acute lymphoblastic leukemia (ALL) characterized by this translocation have been studied to determine its prognostic significance with confidence.
  • We therefore report three new patients (two male children and one adult female) and present their hematologic, immunophenotypic, and clinical data.
  • The clinical and laboratory characteristics of 26 other patients with t(8;14)(q11.2;q32) are summarized.
  • The total number of patients now reported in the literature is 29 with a mean age of 14 years.
  • Twenty-three t(8;14) patients show a pre-B immunophenotype and 24 of 24, on whom information is available, achieved complete remission after induction chemotherapy for B-ALL.
  • Approximately one third of patients with t(8;14) have Down syndrome, 19 of 27 have additional acquired cytogenetic abnormalities, 5 of these have the t(9;22), and 4 show duplication of the abnormal chromosome 14, which is derived from the t(8;14).
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12581891.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


88. Latorre C, Sanfeliu I, Grupo de Trabajo de Hospitales Comarcales de Cataluña: [Haemophilus influenzae: phenotype characteristics of strains isolated in 12 Catalan hospitals over one year]. Enferm Infecc Microbiol Clin; 2003 Mar;21(3):126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Haemophilus influenzae: características fenotípicas de las cepas aisladas en 12 hospitales catalanes durante un año.
  • Surveillance of ciprofloxacin susceptibility is required to predict therapeutic failures with this quinolone.
  • [MeSH-major] Drug Resistance, Bacterial. Haemophilus Infections / microbiology. Haemophilus influenzae / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ampicillin Resistance / genetics. Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Antigens, Bacterial / immunology. Bacterial Capsules. Bacterial Proteins / analysis. Bacterial Proteins / genetics. Bacterial Typing Techniques. Body Fluids / microbiology. Child. Child, Preschool. Cross Infection / drug therapy. Cross Infection / epidemiology. Cross Infection / microbiology. Drug Resistance, Multiple, Bacterial / genetics. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Phenotype. Serotyping. Spain / epidemiology. Urease / analysis. beta-Lactamases / analysis. beta-Lactamases / genetics

  • Genetic Alliance. consumer health - Haemophilus Influenzae.
  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Haemophilus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Enferm Infecc Microbiol Clin. 2003 Mar;21(3):123-5 [12586015.001]
  • (PMID = 12586016.001).
  • [ISSN] 0213-005X
  • [Journal-full-title] Enfermedades infecciosas y microbiología clínica
  • [ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; EC 3.5.1.5 / Urease; EC 3.5.2.6 / beta-Lactamases
  •  go-up   go-down


89. Zhou A, Scoggin S, Gaynor RB, Williams NS: Identification of NF-kappa B-regulated genes induced by TNFalpha utilizing expression profiling and RNA interference. Oncogene; 2003 Apr 3;22(13):2054-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor alpha (TNF alpha) is a proinflammatory cytokine with important roles in regulating inflammatory responses as well as cell cycle proliferation and apoptosis.
  • Since several chemotherapy agents act like TNFalpha to both promote apoptosis and activate NF-kappa B, understanding the role of NF-kappa B in suppressing apoptosis may have significant clinical applications.
  • Real-time PCR verified expression changes in 16 of these genes and revealed three distinct temporal patterns of expression after TNFalpha stimulation.
  • Inflammatory, proapoptotic, and antiapoptotic genes were all shown to be regulated by NF-kappa B, demonstrating the wide variety of targets activated by NF-kappa B signaling and the necessity of differentiating among these genes for therapeutic purposes.
  • [MeSH-minor] Computer Systems. HeLa Cells / drug effects. HeLa Cells / metabolism. Humans. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Transcription Factor RelA. Tumor Necrosis Factor-alpha / pharmacology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncogene. 2004 Dec 16;23(58):9447
  • (PMID = 12673210.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA74128
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


90. Chen X, Hu X, Zou Y, Pi R, Liu M, Wang T, Zheng X, Liu M, Lin M, Liu P, Tao L: Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. J Neuroimmunol; 2009 May 29;210(1-2):22-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice.
  • There has been enormous progress in the treatment of multiple sclerosis (MS) in recent years, but further improvement in therapy is still required because not all patients respond optimally to existing treatments.
  • Increasing evidence has demonstrated that combination therapies produce a more favorable clinical outcome than monotherapy in MS treatment.
  • Minocycline is effective in experimental autoimmune encephalomyelitis (EAE), and is a promising candidate for future MS medication.
  • Glucocorticosteroids (GCS) belong to the most potent immunosuppressive drugs and are the mainstay for treatment of acute relapses in MS.
  • Our findings showed that the combination of these two drugs functioned better than when they were individually administered in EAE mice, as evidenced by decreased clinical scores, reduced inflammation and demyelination, and improved magnetic resonance imaging outcomes.
  • Further studies revealed that the combined treatment prevented the reduction of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA expression in cerebral cortex of EAE mice.
  • In conclusion, our findings indicated that this combination therapy suppressed disease severity of EAE partially through blocking the downregulation of neurotrophic factor expression, suggesting that the combination of minocycline and prednisone could be a novel treatment in MS.
  • [MeSH-major] Encephalomyelitis, Autoimmune, Experimental / drug therapy. Immunosuppression / methods. Minocycline / pharmacology. Prednisone / pharmacology
  • [MeSH-minor] Animals. Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents / pharmacology. Anti-Inflammatory Agents / therapeutic use. Brain-Derived Neurotrophic Factor / genetics. Central Nervous System / drug effects. Central Nervous System / immunology. Central Nervous System / pathology. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Down-Regulation / immunology. Drug Therapy, Combination. Female. Magnetic Resonance Imaging. Mice. Mice, Inbred C57BL. Nerve Fibers, Myelinated / drug effects. Nerve Fibers, Myelinated / immunology. Nerve Fibers, Myelinated / pathology. Nerve Growth Factor / genetics. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neuroimmunol. 2009 Oct 30;215(1-2):130
  • (PMID = 19344957.001).
  • [ISSN] 1872-8421
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 0 / Brain-Derived Neurotrophic Factor; 0 / RNA, Messenger; 9061-61-4 / Nerve Growth Factor; FYY3R43WGO / Minocycline; VB0R961HZT / Prednisone
  •  go-up   go-down


91. Fehr T, Jacky E, Bächli EB: Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia. Ann Hematol; 2003 Mar;82(3):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia.
  • Low-dose methotrexate (MTX) is used as disease-modifying therapy in severe rheumatoid arthritis and as maintenance treatment in patients with complete remission of acute lymphoblastic leukemia (ALL).
  • It is generally well tolerated, but in 27% of patients acute pneumonitis leads to discontinuation of treatment.
  • She was treated with induction chemotherapy in July 1999 which lead to complete remission.
  • Maintenance treatment with low-dose MTX and 6-mercaptopurine (6-MP) was started in December 1999.
  • Computed tomography of the lungs revealed interstitial infiltration and ground-glass opacities.
  • Acute pneumonitis was diagnosed, and MTX was stopped.
  • Prednisone therapy lead to rapid clinical amelioration of dyspnea and hypoxemia.
  • Since for this patient there was no alternative leukemia therapy, MTX was successfully reintroduced in August 2000 without reappearance of any respiratory symptoms.
  • We discuss risk profile, clinical and histological presentation, and therapy of MTX-induced pneumonitis.
  • [MeSH-major] Methotrexate / administration & dosage. Methotrexate / adverse effects. Pneumonia / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Acute Disease. Female. Humans. Middle Aged. Prednisone / therapeutic use. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12634957.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Israëls T, Chirambo C, Caron H, de Kraker J, Molyneux E, Reis R: The guardians' perspective on paediatric cancer treatment in Malawi and factors affecting adherence. Pediatr Blood Cancer; 2008 Nov;51(5):639-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The guardians' perspective on paediatric cancer treatment in Malawi and factors affecting adherence.
  • BACKGROUND: Abandonment of paediatric cancer treatment is a common problem in developing countries.
  • Little is known about the guardians' perspective on cancer treatment in these countries, especially the factors that affect adherence.
  • Semi-structured interviews (n = 83) and focus group discussions (n = 8) were held with the guardians of 25 Burkitt lymphoma patients and 7 Wilms tumour patients at different phases of therapy in Malawi.
  • RESULTS: Parents in Malawi are very motivated to continue treatment if they think that it will cure their child.
  • The diagnosis of cancer was unknown before being told about it in hospital and caused fear of recurrence and death.
  • The side effects of the chemotherapy are seen as a proof of efficacy.
  • CONCLUSION: It is important to appreciate the guardians' concerns when offering treatment that requires their sustained commitment.
  • It is necessary to provide not only medical treatment, but also travel allowances and adequate nutritional support during long hospital stays to impoverished families.
  • [MeSH-major] Developing Countries. Health Knowledge, Attitudes, Practice. Legal Guardians / psychology. Neoplasms / therapy. Patient Compliance / statistics & numerical data
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / economics. Child. Decision Making. Humans. Malawi. Pilot Projects

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668516.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Liu X, Tang Z: BCL-1 rearrangement in acute lymphocytic leukemia and its clinical significance. J Tongji Med Univ; 2001;21(4):283-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCL-1 rearrangement in acute lymphocytic leukemia and its clinical significance.
  • BCL-1 rearrangement (BCL-1/IgH gene rearrangement) in acute lymphocytic leukemia and its clinical significance was investigated.
  • In 38 patients with acute lymphocytic leukemia (ALL), the genomic DNA of mononuclear cells isolated from peripheral blood and bone marrow was amplified by using hemi-nested polymerase chain reaction (PCR) technique and the expression of cyclin D1 protein of mononuclear cells was detected by using immunohistochemical method.
  • Ten patients with acute granulocytic leukemia, 2 with chronic granulocytic leukemia and 10 with normal bone marrow served as control group.
  • Three ALL patients with BCL-1 rearrangement were all B-cell leukemia (B-ALL) and accompanied by cyclin D1 protein expression.
  • No BCL-1/IgH rearrangement or cyclin D1 protein expression was detected in 12 patients with granulocytic leukemia and 10 cases of normal bone marrow.
  • Leukocyte counts in peripheral blood of B-ALL patients with BCL-1 rearrangement and (or) cyclin D1 protein expression were significantly increased and the patients had bad reaction to chemotherapy.
  • 1) BCL-1/IgH gene rearrangement were detected in acute B lymphocytic leukemia;.
  • [MeSH-major] Gene Rearrangement. Genes, bcl-1 / genetics. Immunoglobulin Heavy Chains / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / genetics. Child. Cyclin D1 / biosynthesis. Cyclin D1 / genetics. Female. Humans. Male. Middle Aged. Phenotype

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12539548.001).
  • [ISSN] 0257-716X
  • [Journal-full-title] Journal of Tongji Medical University = Tong ji yi ke da xue xue bao
  • [ISO-abbreviation] J. Tongji Med. Univ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


94. Kaul P, Javangula K: Burkitt lymphoma masquerading as cardiac tamponade. J Cardiothorac Surg; 2007;2:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma masquerading as cardiac tamponade.
  • A 61 year old man presented with diffuse large B cell lymphoma of the skin of the back of the shoulder which was excised and treated with chemotherapy (CHOP regime) in 1998.
  • He was in complete remission till he presented in 2002 with extranodal marginal zone lymphoma of the parotid gland for which he underwent superficial parotidectomy and radiotherapy.
  • At median sternotomy, pericardial effusion was drained, an anterior pericardiectomy was done and a left posterior pericardial window made, and an enlarged hard paraaortic lymph node excised.
  • Histology, immunocytochemistry and chromosome analysis revealed Burkitt lymphoma.
  • Patient underwent chemotherapy with CODOX-M regime and continues in remission.
  • This report is unusual on account of the highly atypical presentation of Burkitt lymphoma as cardiac tamponade, only a few cases having been reported previously, the occurrence of three lymphomas of different pathological and genomic profiles in one patient over a period of eight years and the relatively slow rate of growth of an otherwise fulminant tumour with high tumour doubling time.
  • A review of literature with special emphasis on chromosomal diagnosis, transformation of other lymphomas into Burkitt lymphoma and mediastinal and cardiac involvement with Burkitt lymphoma is presented.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cardiac Tamponade / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Coll Physicians Surg Pak. 2006 Aug;16(8):536-7 [16899184.001]
  • [Cites] Indian J Med Sci. 2006 Sep;60(9):380-4 [16940688.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):347-51 [12063708.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):771-6 [12118116.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):456-61 [12447675.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Feb;141(1):86-8 [12581905.001]
  • [Cites] J Am Soc Echocardiogr. 2003 Dec;16(12):1326-30 [14652615.001]
  • [Cites] Int J Cancer. 1980 Jun 15;25(6):711-9 [14768699.001]
  • [Cites] Leuk Res. 2006 Nov;30(11):1417-23 [16697040.001]
  • [Cites] Cytopathology. 1990;1(4):239-42 [2101671.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1748-55 [7564520.001]
  • [Cites] Rinsho Ketsueki. 1997 Sep;38(9):757-62 [9364867.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):178-82 [15287031.001]
  • [Cites] Ann Surg. 1982 Jul;196(1):82-6 [7092357.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Dec;29(2):245-51 [3677046.001]
  • [Cites] Conn Med. 1990 Apr;54(4):186-9 [2347184.001]
  • [Cites] Rinsho Ketsueki. 1990 Oct;31(10):1731-5 [2255064.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1084-92 [16862570.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • (PMID = 17615068.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1934902
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


95. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM: Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res; 2003 Dec 15;9(17):6567-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
  • PURPOSE: The purpose of this research was to test the therapeutic efficacy of an anthracycline-antibody conjugate for the treatment of human B-cell lymphoma in a preclinical animal model.
  • EXPERIMENTAL DESIGN: Doxorubicin (dox) conjugates of the murine and humanized versions of the anti B-cell antibody LL1, targeting CD74, were prepared, along with a nonspecific control dox-antibody conjugate, targeting carcinoembryonic antigen.
  • Antibody conjugates carried approximately 8-10 drug molecules attached site-specifically at thiols of reduced interchain disulfide bonds.
  • Conjugates were tested, initially in vitro, and then for therapeutic efficacy in a systemic model, using a lethal i.v. dose of Raji cells in SCID mice.
  • RESULTS: Dox-LL1 conjugates were shown to be stable and 3-fold more effective in vitro against the human B-cell Burkitt's lymphoma line, Raji, compared with the nonspecific control conjugate that did not target CD74 or B cells.
  • When SCID mice were given an i.v. dose of 2.5 million Raji cells, they would die of disseminated disease within 15-25 days postinjection.
  • A single dose of dox-LL1 conjugate, 117-350 micro g, given 5 days to 14 (advanced disease) days after injection of the Raji cells resulted in cure of most animals out to 180 days after injection of the cells, whereas animals in treatment control groups were not cured.
  • The dose of dox-LL1 found useful in this work corresponds with a significantly lower drug dose than reported previously with other drug-antibody conjugates CONCLUSION: CD74 appears to be a uniquely useful target antigen for delivery of drugs, effecting cures of animals with single, low doses of conjugate.
  • [MeSH-major] Anthracyclines / pharmacology. Antigens, Differentiation, B-Lymphocyte / chemistry. Histocompatibility Antigens Class II / chemistry. Lymphoma, B-Cell / immunology
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / therapeutic use. Antibodies, Monoclonal / chemistry. Disulfides / chemistry. Doxorubicin / pharmacology. Humans. Immunohistochemistry. Immunotherapy. Mice. Mice, SCID. Models, Chemical. Neoplasm Transplantation. Neoplasms, Experimental / therapy. Time Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14695162.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Disulfides; 0 / Histocompatibility Antigens Class II; 0 / invariant chain; 80168379AG / Doxorubicin
  •  go-up   go-down


96. Wulff EA, Simpson DM: Peripheral neuropathy associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma. Muscle Nerve; 2000 Nov;23(11):1764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral neuropathy associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma.
  • Peripheral neuropathy associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma usually occurs as a toxic effect of chemotherapeutic agents.
  • Whereas primary peripheral nerve involvement is an unusual complication, we report on a human immunodeficiency virus (HIV)-positive patient with Burkitt's lymphoma and sciatic neuropathy due to compression by a lymphomatous mass.
  • Therapy with radiation and chemotherapy was followed by clinical and radiological improvement, but recurrent neurological deficits in a similar distribution occurred later from lymphomatous meningitis.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / complications. Lymphoma, AIDS-Related / complications. Nerve Compression Syndromes / etiology


97. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R: Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res; 2007 Nov 15;67(22):10939-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.
  • Combination chemotherapy regimen incorporating CD20 antibodies are commonly used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL).
  • Fludarabine phosphate (F-araAMP), cyclophosphamide, and CD20 antibodies (Rituximab) constitute the FCR regimen for treating selected NHL, including aggressive mantle cell lymphoma (MCL).
  • This vector was also armed with the prodrug convertase purine nucleoside phosphorylase (PNP) that locally converts the active metabolite of F-araAMP to a highly diffusible substance capable of efficiently killing bystander cells.
  • We showed in infected cells that early prodrug administration controls vector spread, whereas late administration enhances cell killing.
  • Enhanced oncolytic potency after extensive infection was shown in a Burkitt's lymphoma xenograft model (Raji cells): After systemic vector inoculation, prodrug administration enhanced the therapeutic effect synergistically.
  • In a MCL xenograft model (Granta 519 cells), intratumoral (i.t.) vector administration alone had high oncolytic efficacy: All mice experienced complete but temporary tumor regression, and survival was two to four times longer than that of untreated mice.
  • Thus, synergy of F-araAMP with a PNP-armed and CD20-targeted MV was shown in one lymphoma therapy model after systemic vector inoculation.
  • [MeSH-major] Antigens, CD20 / biosynthesis. Lymphoma / drug therapy. Lymphoma / metabolism. Measles virus / metabolism. Vidarabine / analogs & derivatives
  • [MeSH-minor] Animals. Antigens, CD46 / biosynthesis. Antineoplastic Agents / pharmacology. Cercopithecus aethiops. Drug Therapy / methods. Humans. Mice. Mice, Transgenic. Prodrugs / pharmacology. Purine-Nucleoside Phosphorylase / metabolism. Vero Cells

  • Genetic Alliance. consumer health - Measles.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006839.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA119170
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD46; 0 / Antineoplastic Agents; 0 / Prodrugs; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


98. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.
  • Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.
  • Although the overall median survival was similar for both groups in the pre-HAART era (HIV-BL, 6.4 months v HIV-DLCL, 8.3 months; P = .43), survival was significantly worse in patients with HIV-BL in the HAART era (HIV-BL, 5.7 months v HIV-DLCL, 43.2 months; P = .0003).
  • In comparison, histology of HIV-BL and no attainment of complete remission were independent poor prognostic factors in the HAART era.
  • CONCLUSION: Survival of patients with HIV-DLCL has improved in the HAART era, along with CD4 count, whereas survival of similarly treated patients with HIV-BL remained poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


99. Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, Pearce C, Sant T, Drayson MT, Bunce CM: Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia; 2009 Feb;23(2):292-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2.
  • B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in older adults, remains largely incurable and novel treatments are urgently required.
  • We previously reported powerful pro-apoptotic actions of bezafibrate (BEZ) and medroxyprogesterone acetate (MPA) against Burkitts lymphoma cells.
  • This action was tumor cell specific, as the drugs had little impact on normal donor cells.
  • BEZ increased prostaglandin D(2) (PGD(2)) synthesis by CLL cells, and treatment with PGD(2) and its antineoplastic derivative 15dDelta(12,14,)PGJ(2) recapitulated BEZ-induced antiproliferative and proapoptotic actions.
  • The potency of BEZ+MPA against CLL cells mirrored that of chlorambucil, and BEZ+MPA combined with chlorambucil was more potent than either treatment alone.
  • Given the known safety profiles of BEZ and MPA, our data warrant further investigation of their potential as novel therapy for CLL.
  • [MeSH-major] Apoptosis / drug effects. Bezafibrate / pharmacology. CD40 Ligand / antagonists & inhibitors. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Medroxyprogesterone Acetate / pharmacology. Prostaglandin D2 / analogs & derivatives
  • [MeSH-minor] Cell Proliferation / drug effects. Drug Combinations. Drug Synergism. Humans. Mitochondrial Proteins. Reactive Oxygen Species. Signal Transduction. Superoxides. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923439.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 15-deoxy-delta(12,14)-prostaglandin J2; 0 / Drug Combinations; 0 / Mitochondrial Proteins; 0 / Reactive Oxygen Species; 11062-77-4 / Superoxides; 147205-72-9 / CD40 Ligand; C2QI4IOI2G / Medroxyprogesterone Acetate; RXY07S6CZ2 / Prostaglandin D2; Y9449Q51XH / Bezafibrate
  •  go-up   go-down


100. Jain M, Singh N, Bhatia A, Arora VK: Histological assessment of dermal nerve damage occurring during multidrug therapy for leprosy. Int J Lepr Other Mycobact Dis; 2000 Jun;68(2):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological assessment of dermal nerve damage occurring during multidrug therapy for leprosy.
  • This is a prospective histomorphological assessment of dermal innervation in biopsies taken before and after multidrug therapy (MDT) from 41 leprosy patients: 35 borderline tuberculoid (BT), 3 borderline lepromatous (BL), 3 lepromatous (LL).
  • Biopsies of the same lesions taken before commencement (diagnostic therapy) and at the end of therapy (check biopsy) were compared.
  • [MeSH-major] Leprosy / drug therapy. Leprosy / pathology. Peripheral Nerves / pathology. Skin / pathology
  • [MeSH-minor] Biopsy. Leprostatic Agents / therapeutic use. Leprosy, Borderline / drug therapy. Leprosy, Borderline / pathology. Leprosy, Lepromatous / drug therapy. Leprosy, Lepromatous / pathology. Prospective Studies

  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11036497.001).
  • [ISSN] 0148-916X
  • [Journal-full-title] International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
  • [ISO-abbreviation] Int. J. Lepr. Other Mycobact. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Leprostatic Agents
  •  go-up   go-down






Advertisement